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Chronic hepatitis has multiple aetiologies which include viral hepatitis (hepatitis B, 
B+D and C), autoimmune hepatitis and drugs. In sub-Saharan Africa the major 
aetiological factor is chronic hepatitis B virus infection. In this region 10-15% of the 
population is chronically infected with the virus and 76% have serological evidence of 
past exposure to the hepatitis B virus. HDV infection has not been documented in 
Southern Africa but studies from Northern Africa show antibody positivity for HDV 
of 21-31 % in patients with chronic HBV infection. Drug-induced hepatitis is also 
increasingly being recognised as a significant entity. 
This study arose from the observation that there are a significant number of patients 
with autoimmune hepatitis on follow-up at the Groote Schuur Hospital liver clinic. 
This group includes patients who test negative for the standard autoimmune markers 
done at Groote Schuur Hospital but have liver histology that is typical of classical 
autoimmune hepatitis. They also show a clinical and biochemical response to steroid 
and azathioprine therapy that is indistinguishable from that seen in classical 
autoimmune hepatitis cases on similar treatment. 
This study is retrospective and covers the period 1978 - 1996. The patients studied are 
those with chronic hepatitis as defined by the International Working Party in 1995, i.e. 
patients with necro-inflammatory disease of the liver lasting at least 6 months. This 
includes hepatitis B, B + D, C, autoimmune hepatitis and drug-induced liver disease. 
Several other liver diseases that may present with clinical and histological features of 
chronic hepatitis are specifically excluded. These include Wilson's disease, Primary 
biliary cirrhosis, Primary sclerosing cholangitis, alpha-1-antitrypsin deficiency, 
alcohol abuse and iron over load states. 
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CHAPTER 1: 
THE SYNDROME OF CHRONIC HEPATITIS 
1:1 DEFINITION AND CLINICAL FEATURES 
Chronic hepatitis is defined as a chronic inflammatory reaction in the liver continuing 
without improvement for at least 6 months (International Working Party 1995). The 
condition has several different causes with all age groups and races being affected. 
Viral Hepatitis B plus or minus D, hepatitis C, autoimmune hepatitis, cryptogenic and 
drug induced hepatitis are the main causes and their proportions vary geographically. 
Chronic hepatitis is frequently asymptomatic. Symptoms, when present, may be 
intermittent or constant and range from mild nonspecific complaints such as malaise, 
lack of energy and poor appetite through to jaundice, abdominal swelling, drowsiness, 
confusion, bleeding and bruising typical of severe liver disease. Physical signs may be 
minimal. Mild liver tenderness is often the only finding. In contrast some patients may 
present with jaundice, ascites and splenomegaly. Biochemical abnormalities are often 
picked up fortuitously. The most common abnormalities are increased plasma alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activity both usually to 
a similar degree (Williams and Hoofnagle 1988, Di Bisceglie and Hoofnagle 1996). 
The albumin and prothrombin international normalized ratio (INR) may be normal 
until hepatic decompensation occurs. Moderately raised serum globulin 
concentrations may indicate chronicity while high levels could suggest autoimmune 
hepatitis. 
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The histological features consist of varying degrees of necrosis, inflammation and 
fibrosis. Hepatocyte necrosis may be focal, confluent, bridging, interface or 
combinations of any of these patterns. The inflammatory cells are predominantly 
mononuclear in nature. 
1:2 CHRONIC HEPATITIS: 
A HISTORICAL PERSPECTIVE 
In 1950 Waldenstrom described young female patients who had chronic hepatitis, 
raised plasma globulins and a plasma cell infiltrate plus cirrhosis on histology. 
Mackay found that these patients demonstrated the LE phenomenon and proposed that 
the disease be termed lupoid hepatitis (Mackay et al. 1956). This led to the disease 
being inappropriately considered to be part of the systemic lupus erythematosus 
spectrum of disease. Confusion in terminology occurred in the 1960's as more studies 
on chronic hepatitis began to document its varied clinical, biochemical and histologic 
features. This led to new terms such as plasma cell hepatitis, active juvenile cirrhosis 
and subacute hepatitis being used to describe the different manifestations of chronic 
hepatitis. 
The term piecemeal necrosis was introduced by Popper and co-workers to describe 
hepatocyte necrosis, the disappearance of parenchymal cells at the periphery of the 
lobule or along fibrous or inflammatory septa. Following their report piecemeal 
necrosis became synonymous with progression to chronic liver disease (Popper et al. 
1960, Paronetto et al. 1962, Schiff Land Schiff ER 1993). It is now thought that other 
forms of cell death, in particular apoptosis, maybe of equal or even greater importance 
(Desmet et al. 1994 ). The histologic patterns of bridging necrosis and multilobular 
necrosis are associated with an increased propensity for progression to cirrhosis 
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(Baggenstoss et al. 1972, Schalm et al. 1977). Portal tract to central vein bridging is 
particularly aggressive compared to portal tract to portal tract bridging (Cooksley et 
al. 1986). The Mayo Clinic Group in 1972 identified bridging necrosis (confluent 
necrosis linking vascular structures) or multilobular necrosis as predictive for the 
development of cirrhosis in chronic hepatitis of more than 10 weeks duration 
(Soloway et al. 1972). 
In 1968 De Groote et al. for the first time attempted to classify chronic hepatitis on the 
basis of his to logic features and introduced the terms chronic persistent hepatitis 
(CPH) and chronic aggressive hepatitis (CAH) into the literature. CPH described 
predominantly portal chronic inflammation with preserved lobular architecture and 
little or no fibrosis. CAH described more severe disease with inflammation extending 
into the parenchyma with piecemeal necrosis, formation of intralobular septa and 
disturbed architecture but no lobular regeneration. The activity was graded as 
moderate or severe based on the degree of necrosis and inflammation. CPH was 
thought to have a better prognosis (De Groote et al. 1968). Popper introduced the term 
chronic lobular hepatitis (CLH) to describe the histological pattern of spotty 
parenchymal necrosis and inflammation with minimal or mild portal inflammation 
(Popper and Schaffner 1971 ). A comparison of the different histologic groups is 
shown in Table 1 (Randall 1994). 
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TABLE: 1 
Comparison of Histologic Groups (Randall 1994) 
Portal Piecemeal Lobular Fibrosis 
Inflammation Necrosis Activity 
Chronic Present None or slight Variable Nil 
Persistent 
Hepatitis 
Chronic Active Present Mild to severe Variable Variable 
/ Aggressive bridging to periportal 
Hepatitis multilobular bridging to 
necrosis cirrhosis 
Chronic 
Lobular Minimal or Nil Mild to Nil 
Hepatitis mild moderate 
1:3 MODERN VIEWS OF CHRONIC HEPATITIS 
Over the years, documentation of the clinical and histologic evolution of chronic 
hepatitis, identification of new aetiologic agents and new diagnostic methods have 
resulted in a need to modify the original classification done by De Groote et al. 
in 1968. The recognition that CAH, CPH and CLH are not distinct diseases by 
themselves, but part of a spectrum of histological activity which can occur in the same 
patient during the course of disease, e.g. chronic hepatitis B, argues for the 
discontinuation of these terms (Scheuer 1991 ). Scheuer proposed that a system that 
takes into account the aetiology of disease, various forms of necroinflammatory 
activity (CAH, CPH and CLH) and architectural changes (fibrosis) would be more 
comprehensive than the individual terms of CAH, CPH and CLH. The most recently 
proposed nomenclature emphasizes an aetiologic terminology and the discontinuation 
of the terms chronic active hepatitis, chronic persistent hepatitis (De Groote et al. 
1968) and chronic lobular hepatitis (Popper and Schaffner 1971 ). These terms have 
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been the basis on which chronic hepatitis has been histologically classified (Desmet et 
al. 1994). By giving numerical scores to describe the intensity of necroinflammatory 
activity and fibrosis, the concepts of grading and staging of histology were also 
introduced (International Working Party 1995, Ishak et al. 1995). This gives a semi-
quantitative and more reproducible assessment of the histological features of a 
particular liver biopsy. 
1:3.1 AETIOLOGY 
The causes of chronic hepatitis are viral hepatitis B, B plus D and C, autoimmune 
hepatitis and drug-induced liver injury (Figure 1). The diagnosis of chronic hepatitis 
should only be made after the proper exclusion of other causes of chronic liver 
disease, which have clinical and histological similarities to chronic hepatitis. The 
differential diagnosis includes genetic disorders with major extra-hepatic 
manifestations (e.g. Wilson's disease, haemochromatosis and alpha-1-antitrypsin 
deficiency), alcoholic hepatitis which has a different histological pattern, primary 
sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) where the major 
pathology is in the biliary system rather than the hepatic parenchyma. Nonalcoholic 
steatohepatitis and graft-versus-host disease in organ transplantation should also be 
considered (Desmet et al. 1994, International Working Party 1995). 
Cryptogenic chronic hepatitis, unclassified as to viral or autoimmune is a chronic 
inflammatory disease of the liver for which no clear distinction between the two 
aetiologies can be made. Many of these patients present with already established 
cirrhosis. Laboratory tests for hepatotropic viruses are negative and should ideally 
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include the HCV-RNA PCR test. Autoantibodies found in autoimmune hepatitis are 
negative although a small minority of these patients may respond to a trial of steroids. 
FIGURE: 1 
Current Aetiological Nomenclature of Chronic Hepatitis 
(International Working Party 1995) 
WELL ESTABLISHED CAUSES 
1. Viral hepatitis 
Hepatitis B 
Hepatitis B and D 
Hepatitis C 
2. Drug- induced hepatitis 
3. Autoimmune hepatitis 
Classic (Type 1) autoimmune hepatitis 
Type 2 autoimmune hepatitis 
Type 3 autoimmune hepatitis 
Cryptogenic steroid responsive hepatitis 
4. Cryptogenic chronic hepatitis, unclassified as to viral or 
autoimmune 
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1:3.2 PATHOPHYSIOLOGY 
1:3.2(a) CHRONIC HBV INFECTION 
The HBV genome is a partially double-stranded circular DNA of about 3200 base 
pairs. It encodes four overlapping reading frames: 
1. S for the surface or envelope gene. 
2. C for the core gene. 
3. X for the x gene. 
4. P for the polymerase gene (Figure 2). 
Following entry of the virus into the cell, the viral genome is delivered to the nucleus 
assisted by a nuclear localization signal in the viral core protein that is activated by 
protein phosphorylation. Viral genome replication and viral protein assembly follows 
and during these processes, small epitopes of HBV proteins (especially HB core 
antigen) are thought to initiate immune responses. The hepatitis B x protein (HBx) is a 
transactivator which is believed to stimulate cellular signal transduction and activation 
of regulatory genes to result in the expression of genes that induce or maintain 
inflammation. This effect is thought to be important in activating gene transcription 
and the development of hepatocellular carcinoma through the rearrangement of 
cellular and viral DNA. Some reports have shown that HBx alters the function of 
tumour suppressor gene p53 (Wang et al. 1994). 
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FIGURE: 2 
Structure Of HBV Genome (Brechot 1996) 
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In HBV chronic hepatitis, the damage is not due to the virus itself. The hepatocyte 
necrosis is due to the host's immune response against the virus. The cellular responses 
are through HLA class I-restricted CD 8+ lymphocytes and HLA class II-restricted 
CD 4+ lymphocytes. The CD 8+ cells respond to HLA class I pathway processed 
HBcAg which is presented on the surface of the hepatocytes. This initiates a cytotoxic 
response mediated through cytokines; perforin release and Fas ligand mediated 
apoptosis. Nonhepatic antigen presenting cells can also process hepatitis B virions 
through the HLA class II pathway to stimulate CD 4+ T cells resulting in damage of 
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infected hepatocytes. The cytotoxic T cell response in those who clear the virus is 
vigorous, polyclonal and multispecific compared to those who develop chronic 
hepatitis (Chisari 1997). The differences in immune responses are due to the variable 
binding affinity of the class I binding groove for the immunodominant HBV peptides. 
In the infected neonate with an immature immune system, 95% become asymptomatic 
carriers while in children infected after the neonatal period but below 6 years, only 
30% are carriers. In adults this figure drops further to only 3-5% (Lee 1997). 
1:3.2(b) CHRONIC HBV and HOV INFECTION 
The hepatitis delta virus (HDV) is a defective RNA virus, which can not be assigned 
to any of the known group of viruses. It resembles viroids and plant satellite viruses 
(Koshy et al. 1991 ). It requires the helper function of HBV ( or other hepadna viruses) 
for its replication and expression. It is a spherical particle of 36nm in diameter, 
slightly smaller than HBV, with a circular 1700 nucleotide single-stranded RNA 
(minus strand). The outer envelope contains HBsAg but also has small, middle and 
large surface proteins. The genome has features of the rolling circle mode of 
replication common to genomes of the plant satellite viruses or viroids, with both 
genomic and antigenomic RNA being produced due to the ability for self-cleavage 
and self-ligation (Taylor et al. 1991). It replicates via RNA-directed RNA synthesis 
by transcription of genomic RNA to a complementary antigenomic RNA (plus 
strand). The antigenomic RNA strand in tum serves as a template for subsequent 
RNA synthesis. The genomic RNA is approximately 10 fold more abundant than the 
antigenomic RNA and remains primarily in the nucleus while the antigenomic RNA is 
within the cytoplasm where it is responsible for delta antigen production (Hess 1993). 
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The interaction between HBV and HDV replication is not clear, but it is known that 
HBsAg synthesis is sufficient to allow HDV production and that when an HBsAg 
carrier is superinfected with HDV, the synthesis of HBV is frequently shut down. This 
is due to an inhibitory effect of the HDV, however the activity of the chronic hepatitis 
is high due to the direct cytopathic effect of the HDV (Sureau et al. 1992). Most of the 
information on HDV comes from in vitro studies and animal models and cannot all be 
extrapolated to the human host. Cell injury is thought to be cytopathic through the 
molecular interactions of HBV and HDV. The development of hepatocellular 
carcinoma in these patients is rare and this may be due to the rapid course of disease 
to liver failure and cirrhosis such that there is no time for the evolution of primary 
liver cancer. 
HDV infection can either be simultaneously with HBV (co-infection) or infection of a 
person already infected with HBV (superinfection). Chronicity following infection is 
varied with co-infection frequently resolving whereas superinfection tends to result in 
chronicity. Host factors may be important in the development of chronicity (Hess 
1993). Superinfection can also transform asymptomatic or mild chronic hepatitis B 
into severe progressive disease and cirrhosis or alternatively can accelerate the course 
of chronic hepatitis B. 
The transmission of HDV can be sexual, perinatal or percutaneous innoculation. HDV 
infection shows 2 epidemiological patterns. In Northern Africa, Southern Europe and 
the Middle East, HDV is endemic among those with hepatitis B infection and 
transmission is mostly by nonpercutaneous means. In the United States and Northern 
Europe meanwhile, HDV infection is confined to persons with frequent exposure to 
blood and blood products such as drug addicts and haemophiliacs (Dienstag and 
Isselbacher 1998). In Africa, there is very little epidemiological data on HDV. Studies 
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from Senegal and Kenya show 21 % and 31 % antibody positivity in chronic HBV 
carriers respectively (Cronberg et al. 1984, Greenfield et al. 1986). In Southern 
Africa, a study looking at Southern African black people with hepatocellular 
carcinoma and matched controls showed no cases of co-infection with HBV and HDV 
(Kew et al. 1984). 
1:3.2(c) CHRONIC HCV INFECTION 
HCV was recognized in the mid 1970s as the cause of post transfusion non-A, non-B 
hepatitis following the use of HB surface antigen assays to screen blood for 
transfusion. The genome was identified in 1989 and only after then did serological 
and polymerase chain reaction tests become available to test for the presence of this 
infection. The virus shows marked genetic heterogeneity with 6 major genotypes that 
differ by 31-34% at the nucleotide level and more than 50 subtypes that differ by 20-
23% in nucleotide sequence being recognized (Table 2). 
TABLE: 2 
HCV genotypes and their distribution (Di Bisceglie 1998) 
GENOTYPE GEOGRAPHICAL PREDOMINANCE 
la USA and developed western countries 
lb USA, Japan, Europe 
2 Most developed countries, but not very common 
3 Rising in prevalence among injection-drug users 
4 Confined to the middle east and north Africa 
5 South Africa 
6 Asia 
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The genome is a single stranded RNA of approximately 10 000 nucleotides in length 
with a single open reading frame that codes for both structural and nonstructural 
proteins. There is homology of some regions of the HCV genome with similarly 
located regions of flavi-viruses genomes (yellow fever, dengue, Japanese B and pesti 
viruses) (Bisceglie 1998, Sharara et al. 1996). Two envelope proteins that coat the 
virus and a nucleocapsid core protein form the structural proteins. The E2/NS 1 region 
has a hypervariable portion that mutates rapidly when the virus is under 
immunological surveillance. This occurs within the E2HV domain of this portion. The 
end result is the formation of quasi-species (nucleoside variability in viruses 
circulating within an individual) due to ongoing viral mutations (Ogata et al.1991 ). 
This ability to mutate and form quasi-species facilitates viral persistance and 
resistance to neutralisation. The nonstructural proteins are involved in viral replication 
with the NS3 gene producing a viral helicase, which is critical for viral replication. 
The 5' end contains an untranslated region of about 341 base pairs which functions as 
an interval ribosomal entry site. This region is highly conserved in the different HCV 
genomes and it makes an ideal target for diagnostic testing. The NS5A is known to be 
a serine phosphoprotein but its function is not clear presently. The NS5B has both 
RNA-dependent polymerase activity and terminal transferase activity (Figure 3). 
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FIGURE: 3 
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Acute infections proceed to chronicity in 80%-85% of cases and recovery does not 
prevent re-infection on subsequent re-exposure (Dhumeaux et al. 1997, NIH 
consensus statement 1997). A direct cytopathic effect by HCV is not proven due 
largely to the absence of cell culture systems. The cellular damage appears to be due 
to an immunological attack as suggested by the presence of cryoglobulin, circulating 
immune complexes and autoantibodies. A role for excess hepatic iron in cell injury or 
resistance to interferon therapy is suggested in some studies (Olynyk et al. 1995, 
Hayashi et al. 1994). Studies from Italy have found an increased prevalence of HCV 
in patients with B cell Non-Hodgkin's Lymphoma (NHL); particularly low grade 
NHL with mixed cryoglobuliaemia (Pazzalo et al. 1994, Ferri et al. 1994 ). However 
similar studies, particularly in Germany, have failed to show such a connection 
(Ellenrieder et al. 1998). 
The precise mechanisms of viral persistence and cellular injury are not well worked 
out. Viral persistence (unlike in HBV infection) is not dependent on integration in the 
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host genome but seems to be due to its ability to mutate and form quasi-species which 
can escape neutralisation by antibodies. To establish a persistent infection, a virus has 
to be able to establish a persistent non-cytopathic infection without disturbing vital 
cellular functions and secondly be able to evade the host's humoral and cellular 
immune response (Oldstone 1991 ). The lymphotrophic characteristics of the virus 
appear to allow the virus to alter immunological response possibly through the 
inhibition of interferon pathways, inhibition of complement pathways, interference 
with HLA expression, altered cytokine production and lymphocyte signal transduction 
(Booth and Thomas 1996, McChesney and Oldstone 1987, Gooding 1992). This 
allows the virus to persist in hepatocytes and T lymphocytes. The transmission of the 
virus by T lymphocytes has been well documented (Helling 1988). 
1:3.2(d) CHRONIC DRUG-INDUCED HEPATITIS 
The mechanisms underlying drug-induced chronic hepatitis are complex and poorly 
understood. This is due in part to a lack of an animal model since these reactions 
appear to be limited to susceptible humans and there is no relationship between the 
ingestion or amount of drug ingested and the occurrence or onset of liver disease. The 
cytochrome P450 system in humans handles ingested toxins and is thus located 
strategically in the liver and gastrointestinal tract, allowing it to digest and breakdown 
liposoluble xenobiotics (small foreign molecules) before they can reach the 
circulation (Robin et al. 1997). The products formed are stable or reactive metabolites 
that may covalently bind hepatic macromolecules to cause direct liver toxicity. The 
superposition of the cytochrome P450 system and immune system in human beings 
means that P450 generated reactive metabolites binding to proteins can modify the 
self of the individual and mislead the immune system. An immune attack against 
CHAPTER: 1 CHRONIC HEPATITIS: LITERATURE REVIEW - 15 -
hepatocytes occurs either against the self (autoimmune targets) or against the 
modified self (neoantigens). The cytochrome P450 system is responsible for oxidation 
and demethylation reactions, which generate hydroxyl groups. Through sulphation or 
glucuronidation reactions, a large water-soluble polar group is attached to the 
hydroxyl group. As a result of these reactions, cytochrome P450 activates drugs like 
hydrallazine and tienilic acid by forming adducts which generate a novel domain on 
the P450 protein. This is recognized by T-cells and induces an immune attack against 
cytochrome P450 in hepatocytes. 
Drug induced chronic hepatitis may present with a spectrum of clinical, serologic and 
histologic features. At the one end of the histological spectrum, the pattern of liver 
injury resembles autoimmune hepatitis (e.g. methyldopa), at the other chronic viral 
hepatitis (e.g. isoniazid). However, most cases of drug-induced liver injury have 
features suggestive of both (Table 3). 
TABLE: 3 
Drugs Implicated in the Aetiology of Chronic Hepatitis 
(Modified from Bass and Ockner 1996) 
FEATURE DRUG EXAMPLES 
Autoimmune-like Methyldopa Tienilic acid 
Nitrofurantoin Phenytoin 
Sulphonamides Diclofenac 
Chronic viral Amiodarone Aspirin 
Hepatitis-like Isoniazid Etretinate 
The number of drugs implicated is continually rising. Chronic liver damage appears to 
be both as a result of continued exposure to the agent and in some cases to a self-
perpetuating process following the exposure. In the latter, removal of the agent may 
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not stop the progression of liver disease (Manns and Obermayer-Straub 1997). 
Methyldopa causes a wide spectrum of dysfunction and liver pathology ranging from 
asymptomatic enzyme elevations to acute and chronic hepatitis. It is well described as 
causing chronic hepatitis with autoimmune features (Maddreyl 977). The liver disease 
is indistinguishable from other causes of chronic hepatitis. Liver injury tends to 
improve on stopping the drug or rarely may progress to cirrhosis or have a fatal 
outcome. The pathogenesis is not known. The major factors involved appear to be 
genetic predisposition, toxic metabolite generation and immune drug hypersensitivity. 
There is evidence for the formation of a quinone which binds and damages proteins. 
Suppressor T-cell function is inhibited resulting in up regulation of antibody 
production. The Coombs' test is positive with the formation of antinuclear and anti-
smooth muscle antibodies (Kirtland et al. 1980). 
1:3.2(e) AUTOIMMUNE HEPATITIS 
Human leukocyte antigens have an antigen-binding groove and the polymorphisms 
studied as HLA types are largely related to specific aminoacid substitutions in and 
around the groove. In autoimmune liver disease, studies have identified specific 
aminoacid substitutions in the antigen-binding groove of human leukocyte antigen DR 
molecules that may clinically determine (I) the severity of disease and (2) disease 
susceptibility through their direct influence on antigen binding. The DR phenotype 
correlates with the age at disease onset, DR 8 appears to be associated with an 
increased frequency of disease. The anti-liver, kidney microsomal autoantibodies 
formed (anti-LKM) are directed against four linear epitopes on cytochrome 
P450 2D6. The adrenal and ovarian failure, which often accompanies this condition, 
may be due to autoantibodies to P450 cytochromes (P450 c 21, P450 sec and P450 
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c 17) in these organs which destroy their normal function (Manns et al. 1991, Manns 
and Obermayer-Straub 1997). The autoantibodies associated with autoimmune 
hepatitis (AIH) are useful in defining patient groups with distinct clinical profiles and 
outcomes thereby assisting clinicians to improve diagnostic accuracy, standardise 
research and may form the basis for rational treatment protocols. Three major groups 
are recognised, Types 1, 2 and 3 which differ significantly in their autoantibody 
profiles, clinical progression and response to medical treatment (Table 4) (Czaja and 
Manns 1995). A cryptogenic group is also recognised. 
Type 1 and 2 constitute 80% and 4% of the group respectively (Krawitt1996, Czaja 
1996). Type 1 is characterised by the presence of smooth muscle antibodies (SMA) 
and/or antinuclear antibodies (ANA) in serum. The presence of antibodies to 
polymerised F-actin being highly specific for the diagnosis. Type 2 is characterised 
by the presence of anti-LKM-1 antibodies and this is mutually exclusive of SMA 
and/or ANA seropositivity. Type 3 represents about 3% of the whole group. It is 
characterised by the presence of antisoluble liver antigen (SLA) which reacts against 
cytokeratins 8 and 18 within the cytoplasm of hepatocytes (see section 1:3.4(e) page 
32). The trigger that sets in motion the autoimmune process is not clear but appears to 
be of viral origin in the setting of a susceptible individual with the appropriate genetic 
make-up. There is support for this from reports in which AIH developed after well-
documented viral hepatitis (Lindberg et al. 1975, Vento et al. 1997) and also the 
demonstration of measles virus-specific nucleic acid sequences in peripheral blood 
lymphocytes of patients with AIH (Robertson et al. 1987). 
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TABLE: 4 
Variants of Autoimmune Hepatitis 
(Czaja and Manns 1995, Czaja 1995,Van Den Berg 1998) 
FEATURES TYPE 1 ( 80%) TYPE 2 (4%) 
Antibody status * Incidence (%) Incidence (%) 
Anti-nuclear 60 0 
Smooth muscle 70 0 
Soluble liver antigen 
0 0 Liver-kidney microsomal 
type l 0 100 
Anti-neutrophil 75-90 ? 
cytoplasmic (ANCA) 
Anti-asialoglycoprotein 80-85 ? 
receptor (ASGPR) 
Auto-antigen status Unknown Cytochrome P450 2D6 
Genetic HLA Al, B8, DR 3, 4 HLA B14, DR3, C4A-QO 
predisposition 
Clinical profile Adults++ 2-14 years 
Two peaks of occurrence Paediatric 
10-20 years Fulminant onset 
45-70 years Lower globulin levels 
High globulin levels 
Prognosis I 
Cirrhosis rate 45% 82% 
Steroid response 70% and related to HLA <70% 
haplotype 
HCV infection% 11 % 44-86% 
Other immunological 17% 34-40% 
disease% 
Women 70% 89% 
Treatment** Steroids alone or steroids Same 
with azathioprine 
* -Van Den Berg 1998. 
** -See also Table 11 page 49. 
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In Southern Europe, the prevalence of anti-HCV positivity is in the region of 80% and 
this is associated with AIH type 2 in 40%-50% of cases in contrast with Northern 
Europe, which has a much lower positivity rate of anti-HCV and prevalence of AIH 
type 2. Unlike the typical profile of type 2 AIH profile of females more than males, 
young age at onset, high LKM-1 antibody titres and a good response to 
immunosuppression, the anti-HCV associated type 2 AIH has a different profile. This 
form of AIH type 2 occurs in an older population, usually older than 40 years with 
more males than females being affected. The disease activity is much lower with a 
poor response to immunosuppression and lower LKM-1 antibody titres. Anti-GOR 
antibodies are often positive in this patient group (Michel et al. 1992). 
Anti-GOR reflects HCV-induced autoimmunity. GOR47-1 is a cDNA clone that was 
isolated in the plasma of chimpanzees infected with HCV and was subsequently 
shown to encode a protein that is able to bind antibodies in patients with acute and 
chronic HCV infection. Its amino acid sequence (GRRGQKAKSNPNRPL) does not 
correspond to the reported sequences for HCV but to that of a single-copy gene of the 
host cellular genome (Mishiro et al. 1990). Anti-GOR is therefore not a proper 
autoantibody but is an anti-HCV core antibody that cross-reacts with a cellular self-
antigen in the host. It is detectable earlier than anti-HCV, is strictly associated with 
replicating HCV infection and the titres correlate with antibodies to HCV-core antigen 
and the necroinflammatory disease activity on liver biopsy. 
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1:3.3 HISTOPATHOLOGY 
Until recently, the use of the terms grading and staging in pathology has been 
restricted to the assessment of neoplasms with respect to the degree of tumour 
differentiation and extent of spread respectively. The use of these terms in chronic 
hepatitis aims at assessing, in a reproducible manner, the histologic features that have 
been shown in studies to impact on the prognosis, disease severity and progression of 
chronic hepatitis. 
Grading is a measure of the severity of the necroinflammatory activity going on and 
as such will fluctuate with disease activity. Staging is an assessment of disease 
progression and hence is a measure of fibrosis and architectural alteration, which 
results from the necroinflammatory process. Staging therefore tends to progress or 
remain stationary. Staging and grading are clearly necessary for prognosis in ordinary 
practice and are vital in the study of chronic hepatitis and in evaluating trials of new 
therapies to allow the comparison of different patient groups and treatment regimens. 
Prognostic information, which influences patient management, can be obtained in a 
more reproducible manner (Ludwig 1995). 
Any grading and staging system should be clinically relevant; reproducible with 
acceptable intra and inter-observer error; and, provide information of clinical and 
scientific use to the management of patients. The most widely quoted and used system 
is the Knodell score or Histological Activity Index (HAI) which scores four 
components of histological lesions. A numerical score gives a reproducible measure, 
which supplements written pathology reports (Knodell et al. 1981 ). The four 
components assessed by this system are shown in Table 5, each with numerical scores 
as shown and a possible total score of 18. Better understanding of disease aetiologies 
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and prognostic markers has resulted in a number of valid criticisms of this system and 
the proposition of modifications. 
TABLE: 5 
Components for Histology Scoring 
(Knodell et al. 1981) 
Component 
Periportal necrosis with or without bridging necrosis 
Intralobular degeneration and focal necrosis 
Portal inflammation 
Fibrosis 





The following problems have been identified with this scoring system. 
1. The first three components represent grading of disease and should be separate 
from fibrosis, which is a staging assessment. 
2. Piecemeal necrosis and bridging necrosis should be assessed separately since they 
are both grading components that are thought to have different prognostic 
implications (Soloway et al. 1972). 
3. More rigorous definitions should be used to reduce variations in observer 
interpretation of histology. 
4. On statistical analysis, cognizance should be taken of the fact that the scoring 
systems are discontinuous variables (Ishak et al. 1995). A proposed scoring 
system based on current understanding of disease pathology is as outlined in 
Tables 6(a) and 6(b). 
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TABLE: 6(a) 
Grading Of Inflammation (Ishak et al. 1995) 
Grading Component 
Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent 
Mild (focal, few portal areas) 
Mild/moderate (focal, most portal areas) 
Moderate (continuous around<50% of portal tracts or septa) 




Focal confluent necrosis 
Zone 3 necrosis in some areas 
Zone 3 necrosis in most areas 
Zone 3 necrosis+ occasional portal-central (P-C) bridging 
Zone 3 necrosis + multiple P-C bridging 
Panacinar or multiacinar necrosis 
Sub-total 
Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
Absent 
One focus or less per IOx objective 
Two to four foci per 1 Ox objective 
Five to ten foci per IOx objective 




Mild, some or all portal areas 
Moderate, some or all portal areas 
Moderate/marked, all portal areas 
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TABLE: 6(b) 
Staging Of Fibrosis (Ishak et al. 1995) 
Chan~e 
No fibrosis 
Fibrous expansion of some portal tracts +/- short fibrous septa 
Fibrous expansion of most portal tracts, +/- short fibrous septa 
Fibrous expansion of most portal areas with occasional portal to portal (P-P) 
bridging 
Fibrous expansion of portal areas with marked bridging P-P and portal to 
central (P-C) 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete 
cirrhosis) 
Cirrhosis, probable or definite 
SCORE 
Sample reporting options for chronic hepatitis would therefore read like: 
. Chronic hepatitis C, mildly active with bridging fibrosis . 










The question of which scoring system to use will arise many times. It seems 
appropriate to continue using Knodell's scoring system with appropriate modifications 
to take into account the need to separate grading from staging features and the 
importance of scoring histologic features known to be of prognostic value in patient 
management. 
Interface hepatitis, portal inflammation, bridging necrosis and cirrhosis are 
illustrated in Appendix C. 
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1:3.4 DIAGNOSIS 
1:3.4(a) HEPATITIS B VIRUS INFECTION 
In sub-Saharan Africa, 10-15 % of the population is chronically infected with hepatitis 
B virus as compared to less than 1 % in northern Europe and North America. The tests 
available for the serologic diagnosis of hepatitis B are HBsAg, HBeAg, HBcAg and 
HBV-DNA assays (Figure 4). 
FIGURE: 4 
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HBsAg is diagnostic of infection but gives no indication of the duration of the disease 
or the replication status of the virus. Infection without HBsAg in serum but positive 
HBV-DNA, is a rare finding, the significance is not clear (Brechot et al. 1985). 
HBeAg is a surrogate marker for active HBV replication and therefore the potential 
for viral infectivity. It may however be absent in infection with a mutant virus which 
cannot synthesize HBeAg. This is due to pre-core region mutations of the HBV 
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genome, which result in the formation of a stop codon (TGG to TAG) at the end of 
the pre-core region preventing HBeAg synthesis. Synthesis of HBcAg is intact since it 
is only the pre-core region that is deleted (see Figure 2). HBeAg is an immune 
telogen and its absence contributes to the development of more aggressive liver 
disease (Feitelson 1994, Liang et al. 1991, and Omata et al. 1991 ). HBcAg IgM 
appears in acute infection but may also be positive in chronic carriers where it is 
indicative of active replicative chronic HBV infection. Lower titres of HBcAg IgM 
are seen in chronic carriers. Anti HB core may be absent in children due to the relative 
immune deficiency which prevents them from making anti-HB core. 
TABLE: 7 
Comparison of Types of Hepatitis B Viral Infection 
(Di Bisceglie and Hoofnagle 1996) 
HEALTHY CHRONIC 







Risk of developing cirrhosis 
Risk of developing HCC 
Candidate for interferon therapy 
HCC = Hepatocellular carcinoma 
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1:3.4(b) HEPATITIS B VIRUS AND HEPATITIS D VIRUS INFECTION 
Infection with HDV can be demonstrated by showing an anti-HDV seroconversion 
through a rising titre or the de novo appearance of anti-HDV. HDV antigen can also 
be identified on liver tissue. HDV antigen is detectable only briefly in the serum after 
acute infection and its presence confirms ongoing HDV replication and potential 
infectivity. This assay is only available in research laboratories. Anti-HDV can take 
up to 30-40 days from the onset of symptoms before being detectable by ELISA 
techniques (Buti et al. 1986) and will also become undetectable the HBsAg is cleared, 
making retrospective diagnosis of HDV infections difficult. 
The presence of HBV core IgM antibodies, although not absolutely specific, are 
suggestive of co-infection when the anti-HDV antibody and HDV antigen are 
positive. In superinfection the HBV core antibodies will be IgG in nature together 
with a positive HDV antigen and anti-HDV antibody (Dienstag and Isselbacher 1998). 
1:3.4(c) HEPATITIS C VIRUS INFECTION 
At present, there are no diagnostic tests available that can test for HCV viral proteins. 
Diagnosis is based on the detection of the patient's antibody to HCV and testing 
directly for the virus RNA. The HCV antibody is not protective and does not confer 
any immunity. A liver biopsy is not required for diagnosis and aminotransferase levels 
by themselves are not helpful since only 40-60% of infected patients have raised 
enzymes and those with normal enzymes may have histological evidence of chronic 
hepatitis. 
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FIGURE: S 
Serological Course of Hepatitis C Infection 
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The commercial kits currently available are reliable and have a sensitivity of almost 
95%. The initial antibody test done is an enzyme immunosorbent assay (EIA) that 
uses four target HCV protein fragments in solution within the patient's serum. The 
fragments assayed are c22-3 of core region, c33c of NS3, cl00-3 and 5-1-1 of NS4 
region (Figures 3 and 6). False negative results with the EIA test can occur due to the 
use of one antigen only (as in cl00-3 with the first generation assays), testing before 
seroconversion occurs and immunosuppression as with HIV or organ transplantation. 
Other problems include viral heterogeneity because current assays are based on the 
type la genotype, which is the most common in the USA. Hypergammaglobulinaemia 
and connective tissue diseases also interfere with the assays (Gross 1995 and 1998). 
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FIGURE: 6 
Hepatitis C Virus Genome and Recombinant Proteins 
(Medina and Schiff 1995) 
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If the EAi test is positive, the presence of antibody is confirmed with a 
radioimmunoblot assay (RIBA) which tests the patient's serum against the same four 
HCV protein fragments attached to a nitrocellulose strip to give a greater specificity. 
If the patient's serum reacts with two or more strips in the RIBA, the test is positive. 
More than 85% of patients with HCV viraemia show reactivity with two or more 
bands on second generation RIBA testing. A reaction with one strip is indeterminate. 
An indeterminate result may be seen in truly infected patients who have less common 
HCV genotypes (Table 8). 
- 28 -
CHAPTER: 1 CHRONIC HEPATITIS: LITERATURE REVIEW 
TABLE: 8 
Interpretation of Serologic Tests for Hepatitis C Viral Infection 
(Di Bisceglie and Hoofnagle 1996) 
Anti-HCV EIA ALT HCV-RNA RIBA Interpretation 
+ t + + Acute/chronic HCV infection 
+ N + + " Healthy carrier" 
+ N + Recovered HCV infection 
+ N False positive 
N = normal, t = Elevated levels, + = Positive test, - = Negative test. 
HCV-RNA TESTS 
Qualitative and quantitative tests are available to assay for HCV-RNA. 
Qualitative tests are designed to be very sensitive so as to pick up any virus present in 
the serum. The most sensitive test is the polymerase chain reaction (PCR) assay. This 
amplifies minute amounts of viral RNA under carefully controlled conditions to avoid 
false-positive and false-negative results. It can detect as few as 50-1000 genome-
equivalents of HCV-RNA per ml of serum. Rapid separation of the serum from 
cellular blood components is important to maintain the integrity of the HCV-RNA 
genome and reduce inaccurate results. The variation in the HCV genome does not 
affect PCR testing because the PCR primers are based on the highly conserved 5' 
untranslated region of the genome. 
Quantitative RNA tests measure the level of viral RNA in the blood. They are best 
suited for monitoring response to treatment and in making therapeutic decisions. 
These tests are less sensitive than PCR and should not be used for screening patients. 
The branched DNA (bDNA) signal amplification system has a reported sensitivity of 
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between 72 to 95% depending on the genotype. The assay can detect HCV-RNA 
down to a level of 1.6 xlO 5 genomes/ml. A low level of HCV-RNA, regardless of 
genotype, predicts those who in the long term are more likely to respond to interferon 
therapy (Lau 1993). 
Immunostaining using polyclonal or monoclonal antibodies can detect HCV antigen 
(HCV Ag) within the liver. Only 60-70% of patients with a high level of HCV-RNA 
in serum are positive on immunostaining. The technique is difficult, has significant 
false positive results and is currently not available for routine clinical use 
(Krawczynski et al. 1992). 
1:3.4(d) DRUG-INDUCED HEPATITIS 
There are no specific tests available to confirm a diagnosis of drug-induced liver 
disease. Animal experiments cannot predict human idiosyncratic reactions and the 
clinical presentation may be with asymptomatic disease or fulminant liver failure. 
Each new drug is potentially hepatotoxic and a high index of suspicion is necessary to 
make a diagnosis (Kaplowitz 1986). Chronic drug-induced liver disease is considered 
to be present when biochemical evidence of liver injury has been present for more 
than 3 months. Biochemical evidence of liver injury is defined as an increase of more 
than twice the upper limit of the normal range of alanine aminotransferase (ALT) or 
conjugated bilirubin, or a combined increase in the aspartate aminotransferase (AST), 
alkaline phosphatase and total bilirubin. This is provided one of them is more than 
twice normal (Benichou 1990). There are no specific clinical features diagnostic of a 
drug aetiology for chronic hepatitis. Rash and fever with eosinophilia, although 
supportive of an acute drug reaction, occur rarely. Other features, which may occur, 
include renal failure, vasculitis and bone marrow suppression. 
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The temporal relationship is the first criterion used to establish an aetiological 
relationship of a drug to an illness. It is important to show that the patient was well 
before ingesting the drug, became ill while taking it and had a striking response after 
its withdrawal (Lee 1995). The latent period between ingestion and illness varies from 
several weeks for most forms of drug-induced hepatitis to more than 6 months in 
cases of chronic liver disease. Although variable, the latent period of many drugs is 
sufficiently reproducible to be of some diagnostic importance. Causality assessment is 
an integral part of the diagnostic process. The assessment attempts to quantify the 
likelihood of a particular disorder having been caused by a given drug. The drug 
history, temporal relationships between exposure, onset and resolution of liver 
abnormalities, clinical features and tests to exclude other causes of hepatobiliary 
disease are analysed to assess the likelihood of a drug being responsible. 
The drug history should include ingested drugs and environmental toxins from present 
and past work environments or through recreational activities. Where more than one 
drug is being taken, it may be necessary to stop all drugs. The time to onset of the 
drug reaction ("challenge"), the course of the reaction after stopping the drug 
("dechallenge") and the response to readministration of the suspected hepatotoxin 
("rechallenge") can be scored and numerical cut-offs given. These can be used to 
define the reactions as suggestive, possible, dubious or incompatible with an adverse 
drug reaction (Benichou 1990). 
Deliberate rechallenge to achieve a diagnosis is harzadous, has significant morbidity 
and mortality, and is not advised (Parrish 1990). From a practical and ethical 
viewpoint, in the individual case, rechallenge may be considered where further 
treatment with the implicated agent is absolutely necessary. Inadvertent rechallenge 
confirms the diagnosis but often with a fatal outcome (Seggie et al. 1979). 
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In vitro tests attempting to profile specific diagnostic tests for drug-induced liver 
disease have yielded conflicting results. No in vitro tests are specific and sensitive 
enough to predict an adverse drug reaction. The tests used presently include 
macrophage migration inhibition, lymphoblastic transformation and autoantibodies 
(LKM-2 antibody, which is anti-P450 2C9 and induced by tienilic acid and anti-liver 
microsomal antibody, which is anti-P450 IA2 induced by dihydrallazine). They all 
lack sensitivity and specificity and clinical use is limited. The individual susceptibility 
to have an idiosyncratic reaction is not necessarily immune mediated and rather 
depends on metabolic idiosyncrasy which consists of many factors impossible to 
measure/quantify in a single test. These include unusual metabolism of a drug, 
impairment of cellular antioxidant mechanisms or inhibition of enzymes that are 
already partially deficient from genetic defects (Farrell 1986). 
Liver biopsy is not a prerequisite for the diagnosis of drug-induced hepatitis. There 
are histologic features that can be used to support such a diagnosis. These include 
microvesicular fatty change, zonal necrotic lesions disproportionate to the clinical 
severity, eosinophilic infiltration, bile duct destruction, granuloma formation and 
'atypical cholestasis' such as cholestasis with hepatitis. Liver biopsy is also useful in 
diagnosing other causes of liver disease in patients who may be coincidentally using a 
potentially hepatotoxic drug. Use is also made of liver biopsy in cases where a drug in 
use for a serious medical condition with limited other choices is suspected of having 
an adverse effect (Farrell 1994 ). 
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1:3.4(e) AUTOIMMUNE HEPATITIS 
Hypergammaglobulinaemia, serum autoantibodies and an unresolving inflammation 
of the liver characterize autoimmune hepatitis. Its clinical and histological features 
resemble those of other acute and chronic liver diseases. The immunological markers 
found in AIH can also be found in liver disease due to other causes. There is no single 
sensitive and specific diagnostic marker of AIH and so the diagnosis is therefore 
mainly one of exclusion. The diagnosis of autoimmune hepatitis implies the absence 
of the other diseases listed in Figure 1 and can only be made from an assessment of a 
combination of clinical, biochemical, serological and histological features (Van Den 
Berg 1998). 
Diagnosis may be difficult due to the many different autoantibodies associated with 
AIH, its co-existence and overlap with other diseases such as PBC and its varied 
clinical presentations. A panel of expects, The International Autoimmune Hepatitis 
Group, in 1992 made recommendations for diagnostic criteria for AIH based on a 
scoring system. This aims at achieving standard diagnostic and treatment approaches 
to AIH by clinicians (Johnson et al. 1993). Clinical, biochemical, immunological, 
virological and histological criteria are scored as well as the response to treatment. 
Points are given for particular features or deducted for conditions suggesting an 
alternative diagnosis. The scoring parameters are outlined in Tables 9(a) and 9(b). 
The autoantibodies used for diagnosis include anti-nuclear antibody (ANA), smooth 
muscle antibody (SMA), liver kidney microsomal antibody (LKM-1 ), soluble liver 
antigen (SLA), liver-pancreas antibody, asialoglycoprotein receptor (ASGP-A) and 
liver cytosol type 1. There is no single and specific diagnostic antibody for 
autoimmune hepatitis. ANA appear to be nonspecific manifestations of increased 
immunoreactivity associated with liver cell destruction (Sturgess 1992, Czaja 1995a). 
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In rheumatic diseases, patterns of ANA immunofluorescence characterize particular 
diseases and have diagnostic specificity. A diffuse pattern being associated with 
systemic lupus erythematosus (SLE), drug-induced SLE, rheumatoid arthritis, 
vasculitis and polymyositis. Mixed connective tissue diseases, Sjogren's syndrome 
and SLE have a speckled pattern. However no particular pattern of ANA indirect 
immunofluorescence positivity has been strongly associated with AIH (Czaja et al. 
1997a). The patterns produced are variable, the most common being the homogeneous 
and speckled type. Younger patients have been shown tend to have speckled patterns 
at presentation but no prognostic value can be attached to individual patterns of 
immunofluorescence. 
Smooth muscle antibodies are formed against actin and nonactin components (tubulin, 
vimentin, desmin and skeletin). When the reactivity is against actin cables in cultured 
fibroblasts, the specificity for AIH is high. The reactivity is against polymerized F-
actin, which is closely associated with the hepatocyte membrane. Nonactin activity is 
common in viral infections and may give low positive SM titres. 
Soluble liver antigen antibodies occur only in patients with AIH but are not mutually 
exclusive of other immunoserologic markers such as ANA and SMA. Their greatest 
value appears to be in assessing patients with cryptogenic chronic hepatitis in who up 
to 18% of cases can be reassigned to an autoimmune category (Manns et al. 1987, 
Czaja et al. 1993). 
No separate criteria are needed for children but it should be noted that lower titres 
than those used in adults are considered significant. It is also important to note that 
overlap with PSC is a problem that needs exclusion with cholangiography. 
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TABLE: 9(a) (Johnson et al. 1993) 










Total serum globulin, gamma globulin or IgG 





Autoantibodies (titres by immunofluorescence on rodent tissues) 
Adults 






ANA or LKM-1 
>1:20 










lgM anti-HA V, HBsAg or IgM anti-HBc positive 
Anti-HCV positive by ELISA and/or RIBA 
Anti-HCV positive by PCR for HCV RNA 
Positive test indicating active infection with any other virus 
Seronegative for all of the above 
Other etiological factors 




Alcohol (average consumption) 
Male <35 gm/day, female <25gm/day 
Male 35-40 gm/day, female 25-40 gm/day 
Male 50-80 gm/day, female 40-60 gm/day 
Male >80 gm/day, female >60 gm/day 
Genetic factors 
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TABLE: 9(b) (Johnson et al. 1993) 
Scoring System for Diagnosis of Autoimmune Hepatitis: Additional Parameters 
Parameter Score 
Histology 
Chronic active hepatitis with piecemeal necrosis 
With lobular involvement and bridging necrosis +3 
Without lobular involvement and bridging necrosis +2 
Rosetting of liver cells +1 
Marked/predominantly plasma cell infiltrate +1 
Biliary changes -1 
Any other changes (e.g., granulomas, siderosis and copper deposits) -3 
suggestive of a different etiology 
Autoantibodies 
In patients who are seronegative for ANA, SMA, and LKM-1 
Any defined "liver autoantibody" (e.g., antibodies to SLA, ASGP-R, 





HLA B8-DR3 haplotype, or DR4 allotype +1 
Response to therapy 
Complete response +2 
Partial response 0 
Treatment failure 0 
No response (in terms of disease activity) -2 
Relapse during or after treatment withdrawal after initial complete +3 
response 
Although invaluable as the basis for scientific studies on the diagnosis and the 
treatment of autoimmune hepatitis, the scoring system's usefulness in general practice 
is still debated. This is due to the fact that the system still has to be prospectively 
validated. Retrospective data from Czaja et al. in 1996 on 119 patients diagnosed with 
AIH by standard criteria and 131 patients with other chronic liver diseases gave 
favourable results. Ninety-seven patients (82 % ) diagnosed as having AIH by 
conventional criteria had a definite diagnosis by the scoring system while 22 patients 
(18%) had a probable diagnosis. Only 2 patients (2%) with other chronic liver disease 
had a score sufficient for a definite diagnosis of AIH (Czaja and Carpenter 1996a). 
However data from Newton et al. 1996, suggests that the proposed criteria may be too 
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stringent and hence could lead to withholding of effective treatment in some patients 
not fulfilling these criteria. The weaknesses noted to date include: 
1. Some laboratory tests are not generally available e.g., HLA typing, LKM-1, SLA-
and ASGPR autoantibodies. 
2. Difficulty in diagnosing the overlap syndromes with other autoimmune disorders 
and liver infections e.g., PSC, PBC and HCV. 
3. Features such as "relapse during or after treatment-induced remission" do not 
assist in deciding whether or not starting therapy is warranted in a new patient. 
4. The scoring of the response to corticosteroid therapy can influence the final post 
treatment diagnosis assigned to the patient and hence the long term outcome. 
In Czaja's validation study of 1996, 22% of the study group (23 out of 107) had a 
probable diagnosis of AIH and these 43% had an upgrade of their diagnosis to definite 
AIH. In 18% of those with a definite AIH diagnosis pre-treatment, there was a 
downgrading to a probable diagnosis of AIH following corticosteroid therapy. This 
highlighted the over emphasis on steroid response. Clinical studies have shown 
clearly that this is not invariably the case. Table 10 shows Czaja's modified scoring 
system for AIH which is less complex, takes out the response to steroids score. The 
other objective is to ensure that the scoring system should be able to make a confident 
diagnosis of AIH prior to therapy and that this diagnosis be maintained in the post 
treatment period (Czaja 1998). 
The association of AIH type 2 and HCV infection is well documented particularly in 
Southern Europe. These patients tend to be older patients, have previous histories of 
blood transfusions and men more than women are affected. They also have lower 
titres of anti-LKM-1 and serum aminotransferases levels compared to classical Type 2 
AIH (Michel et al. 1992, Lunel et al. 1992). 
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Differentiation between the two depends heavily on serological characterization. 
There is significant overlap in ANA and SMA positivity with generally lower titres in 
patients with chronic HCV infection. The circulating immunoglobulins may 
occasionally be as high as those seen in AIH. The HCV- PCR is positive and the liver 
biopsy is helpful in the sense that HCV infection is suggested by the presence of 
portal tract lymphoid aggregates, mild microvesicular steatosis and severe bile duct 
damage or loss (Shapiro and Friedman 1996). A recent study by Czaja and Carpenter 
1997, has shown that patients with AIH had more marked portal, interface and acinar 
hepatitis in various combinations associated with a plasma cell infiltrate compared to 
other causes of chronic hepatitis. They also had higher serum levels of gamma 
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1:4. MEDICAL THERAPY 
The early diagnosis and recognition of chronic hepatitis is crucial for successful 
treatment and outcome. This is important considering that a significant number of 
patients are diagnosed only when they present with established cirrhosis and portal 
hypertension with some in this group having presented earlier but the diagnosis 
having been missed entirely. 
The armamentarium available for the management of chronic hepatitis include: 
(a) Early clinical recognition. 
(b) Immunization. 
(c) Immunosuppression with steroids and azathioprine. 
(d) Interferon and second-generation nucleoside analogues. 
( e) Liver transplantation. 
The management of the complications associated with chronic hepatitis often ends up 
as the major function of the attending Physician. The major ones are portal 
hypertension with ascites, bleeding varices, hepatocellular carcinoma, osteoporosis 
and liver failure. 
The early recognition of the syndrome is important with drug-induced hepatitis (for 
the immediate withdrawal of offending drug), viral hepatitis (to enable the early use 
of interferon before the onset of cirrhosis) and in AIH for early use of 
. . 
1mmunosuppress1on. 
Immunisation to date has only been successful with HBV infection. Nationwide HBV 
vaccination in Taiwan using plasma-derived HBV vaccine in infants (at birth, one and 
six months), children and adults over a ten year period reduced the incidence of 
hepatocellular carcinoma (HCC) significantly. The average annual incidence of HCC 
CHAPTER: 1 CHRONIC HEPATITIS: LITERATURE REVIEW - 41 -
in children of 6-14 years was reduced from 0.70 per 100 000 children to 0.36 over this 
period (Chang et al. 1997). No vaccine is presently available for HCV due to the 
marked genetic heterogeneity shown by this virus. 
1:4(a) HBV INFECTION 
Interferon a-2b(IFN) therapy for chronic HBV and HCV infection is still evolving. 
Interferon a-2b induces the display of HLA class I molecules on the membranes of 
infected hepatocytes, promoting their lysis by CD 8+ cytotoxic T cells which can also 
inhibit viral protein synthesis directly. For HBV infection, IFN is the most effective 
treatment presently. It is able to achieve a 36% - 45% biochemical response rate, with 
only 10% loosing the HBsAg entirely. In untreated patients, only 5%-10% improve 
spontaneously and rarely do they loose their HBsAg. The patient groups who show 
the best response are those with: 
(a) Well compensated disease. 
(b) Detectable HBsAg and HBeAg in serum. 
(c) Lower HBV-DNA levels at less than 200 pg/ml. 
(d) Raised aminotransferase levels of more than 100 iu/ml (Response doubles if AST 
is more than twice normal). 
( e) Short duration of disease of less than 1 year. 
(f) Caucasian origin (Low response in Asians has been documented). 
(g) No immunosuppression (HIV infection and transplants) (Brook et al. 1989). 
(h) No HDV or HCV co-infection. 
(i) Adult acquired disease and female sex. 
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Recent studies on the treatment of chronic hepatitis B infection in Asian patients with 
IFN have shown that the response rates are somewhat better than was initially 
reported in the early studies in Asian children (Lai et al. 1987 and 1991, Liaw et al. 
1994 ). A recent randomised controlled study by Martin et al. 1998 compared the 
response rates in Asian-American adults with chronic HBV infection to a control 
group of Caucasian adults treated with the same antiviral regimen of prednisone 
withdrawal therapy initially followed by IFN a2b. The results showed that the initial 
response rates are identical with 62% of Asians and 60% of Caucasians clearing 
HBeAg and HBV DNA from the serum. At one year follow-up 67% of Caucasian 
responders and none of the Asian ones had cleared HBsAg from their serum. The loss 
of serum markers of active HBV replication was less sustained in the Asian 
responders as shown by the reappearance of serum HBeAg in 25% of Asians and 17% 
of Caucasians. This suggests that prolonged or combined therapy may be necessary in 
these patients to achieve better results. 
The contra-indications to treatment with interferon include: 
1. HIV infection associated with neutopaenia. 
2. Severe liver disease with decompensation. 
3. Serious medical illness such as renal failure, uncontrolled hypertension and heart 
disease. 
A poor response is also associated with male sex, perinatally acquired disease, and the 
presence of anti-HBe, normal ALT and co-infection with HDV and HCV. 
The recommended doses are 5Mu subcutaneously (sc) daily or lOMu three times per 
week to complete a 16 week course. Pre-treatment a liver biopsy is needed to exclude 
other conditions that may cause a chronic hepatitis and to stage the disease. Base-line 
thyroid function tests and full blood count (FBC) are also necessary. The side effects 
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include depression, flu-like illness, hypothyroidism, neutropaenia and 
thrombocytopaenia. An axonal polneuropathy has been reported in the literature. 
Monitoring with FBC and serum aminotransferases should be done weekly for the 
first 4 weeks, two weekly for next 8 weeks and four weekly thereafter. The 
aminotransferases reach levels of 2-5 times above the starting baseline when the 
HBV-DNA and HBeAg are being cleared. If the side effects are intolerable, the IF 
dose should be reduced by half. 
Nucleoside analogues are gaining increasing use in a bid to try and improve the 
response rates to treatment. They block reverse transcription of RNA and the most 
promise has been shown with the less toxic second generation group of lamuvidine 
and famciclovir. Lamuvidine alone for 4-12 weeks has been shown to clear HBV-
DNA virtually by 100% but with very high relapse rates-only 19% achieving 
sustained remission (Dienstag et al. 1995). There is also a high mutation rate with 
longer-term treatment with at least 16% of the patients at one year having an 
associated recurrence in viraemia. The data from liver transplant patients suggests that 
nucleoside analogue treatment will need to be continued indefinitely (Honkoop et al. 
1998). This has the attendant problems of cost and a high rate of mutations. 
Combination therapy with two different types of interferon or of two nucleoside 
analogues has been suggested but presently there is no data to support this as a better 
treatment. 
The use of steroids for treating viral hepatitis reduces survival and fatal exacerbations 
can occur when the steroids are withdrawn. A few patients have been shown to clear 
their HBeAg and HBV-DNA during this withdrawal phase. Some workers have tried 
to take advantage of this phenomenon by combining steroid-withdrawal therapy and 
interferon alpha-2b with no real benefit being observed (Perrilo et al. 1990). 
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1:4(b) HCV INFECTION 
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In the treatment of HCV, interferon is the most widely accepted therapy although the 
relapse rates are significantly high. At the end of treatment 40-50% have normal 
aminotransferase levels with 30% showing a histopathological response. Only 15-
20% will show a sustained response-that is, persistently normal serum 
aminotransferase concentrations and the absence of HCV RNA from serum at the end 
of treatment and sustained for at least six months (Brown 1998). Studies would 
suggest that prolonged courses of 18-24 months are needed to maximize the chances 
of having a sustained response to treatment (Poynard et al. 1995). 
HCV has become the leading reason for liver transplantation in the USA. The natural 
history of untreated infection is cirrhosis after 21 years and the development of 
hepatocellular carcinoma at 29 years post infection. If infection occurs after the age of 
40 years, cirrhosis develops in about 13 years in men and after 42 years in women 
who do not use alcohol. The sex difference is unexplained but alcohol is a significant 
co-factor in disease progression together with the viral load and the genotype 
(Poynard et al. 1997, Wiley et al. 1998). 
Various indicators have been shown to predict good or poor response to interferon 
therapy. Poor response is predicted by: 
I. Long duration of disease pretreatment (more than 10 years). 
2. Associated HIV infection/immunosuppression of whatever cause. 
3. Cholestasis. 
4. Iron overload. 
5. Presence of cirrhosis. 
6. High level of viral multiplication (HCV RNA levels of >3million genomes/ml). 
7. Genotype lb. 
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8. High gammaglutamyl transferase levels. 
The absence of the above predicts good response together with: 
1. Lower body weight. 
2. Genotypes 2 and 3 infections. 
3. Mutations in the NS5 region. 
4. Mild inflammation which is limited to the portal tracts. 
5. Reducing HCV RNA levels after 12 weeks of therapy. 
6. Prolonged treatment of 12-18 months (Kasahara et al. 1995, Poynard et al. 1995). 
Doses of interferon higher than 3 million units three times per week do not improve 
the response rate and in non-responders, a second course is usually ineffective. Those 
who initially respond and then relapse may show a response on re-treatment. However 
caution should be observed in patients with established cirrhosis due to the risk of 
having a rebound of the activity of chronic hepatitis on stopping interferon (Macellin 
et al. 1991 ). A recent NIH conference on the management of chronic hepatitis C 
recommends treatment of those with compensated cirrhosis and other cirrhotics only 
under close supervision (NIH consensus statement Hepatology 1997). The different 
forms of interferon are not necessarily dose equivalent. Recombinant IFN alpha-2b 
and natural lymphoblastic IFN are of similar potency while recombinant IFN alpha-2a 
and consensus IFN need doses which are 2-5 times higher (Bacon et al. 1995, Tong et 
al. 1995). 
The controversy of how to manage patients with normal or minimally elevated serum 
aminotransferase levels was recently addressed by a pilot randomised controlled study 
from Italy. This study showed that IFN alpha-2a treatment of HCV RNA carriers with 
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persistently normal transaminase levels for 6 months did not eradicate HCV RNA in 
these patients, instead it caused an ALT flare-up in 60% of them (Sagiovanni et al. 
1998). 
Alternatives to interferon have been considered for some time due to the poor 
response rates, cost and side effects that are associated with IFN. Combination 
treatment with ribavirin, n-acetylcysteine, iron-reducing treatments, ursodeoxycholic 
acid and nonsteroidal anti-inflammatory agents have all been looked at with variable 
outcomes. The best results have been obtained with ribavirin, which is a guanosine 
analogue with a broad spectrum of activity against RNA and DNA viruses. Its use for 
chronic HCV as single therapy was first reported in 1991.A 60% reduction in 
aminotransferase levels was achieved with some cases showing HCV RNA serum 
levels reduction. The relapse rate however was 100% on stopping treatment (Di 
Bisceglie et al. 1995, Richard et al. 1991). It is not clear how ribavirin enhances the 
effect of IF but this may be through cytokine modulation. A recent randomised, 
double-blind trial comparing interferon alone with interferon plus ribavirin in 
previously untreated patients showed that at 1 year post treatment, viral clearance 
rates were 42% for the combination therapy group and 20% for the interferon only 
group. This response rate was achieved mainly by those patients who had high viral 
titres of more than 3 Million genomes/ml (12/29 in the combination group vs 1/26 on 
interferon alone). Kinetic studies of HCV showing the high rates of viral turnover and 
rapid evolution of quasi-species (conferring possible drug resistance) suggest that like 
in HIV infection, combination therapy is likely to be the way forward. The 
development of inhibitors to the viral protease, helicase or RNA-dependent 
polymerase will enable such combinations to become a reality (Brown 1998, Reichard 
et al. 1998). McHutchison et al. 1998 have also recently shown similar results for 
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initial therapy of HCV. The response of genotype 1 to combination treatment was 
markedly improved to 28% compared to only 7% with IFN only therapy. In the 
treatment of relapsed HCV following IFN therapy, combination therapy with ribavirin 
gave better outcomes compared to IFN alone. The sustained virologic, biochemical 
and histologic response rates at 24 weeks follow-up were higher in the combination 
group at 49% compared to only 5% in the IFN group (Davis et al. 1998). 
1:4(c) DRUG-INDUCED HEPATITIS 
Diagnosis is the essential prerequisite for the treatment of a drug-induced chronic 
hepatitis. Prevention and early detection are important through appropriate dose 
adjustments for age and sex, assessing for pre-existing renal and liver disease, 
biochemical monitoring and a high index of suspicion. 
Specific therapy centers around stopping the causative drug permanently. The use of 
antidotes is only appropriate in acute hepatic injury and is not applicable in chronic 
drug-induced hepatitis. Corticosteroids, although untested in controlled trials, have 
been used for patients with severe and protracted disease. Case series studies have 
shown limited benefit in chronic disease due to methyldopa, nitrofurantoin and 
dantrolene (Bemuau et al. 1986, Maddrey and Boitnott 1977). Case reports involving 
NSAIDS (diclofenac) and allopurinol have shown some benefit with histological 
improvement being shown after 3 months of treatment (Sallie et al. 1991 ). Most 
benefit appears to be more in cases of hepatocellular type injury that is not improving 
in 6 weeks to 3 months, rather than in cases with cholestatic disease. 
Supportive therapy including rest, nutritional support, vitamin K and fresh frozen 
plasma should be used as required. Progressive deterioration to hepatic 
encephalopathy requires liver transplantation. The outcome is good (Mutimer and 
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Elias 1992) but associated medical conditions for which the drug was originally 
prescribed or psychological instability causing self-poisoning would preclude 
transplantation. 
1:4(d) AUTOIMMUNE HEPATITIS 
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Immunosuppression is the mainstay of therapy in AIH. The drugs used are 
corticosteroids and azathioprine used alone or in combination. When the patient has 
no symptoms and the histology shows only mild inflammation, no treatment is needed 
as long as careful monitoring for possible disease progression is done biochemically 
and histologically. The initial treatment can either be monotherapy with steroids or a 
combination of steroids and azathioprine (Table 11). Maintenance treatment can be 
monotherapy with prednisone 5-15mg daily or azathioprine 100-200mg daily. 
Combination maintenance treatment is prednisone 5-10mg with azathioprine 50-
150mg daily (Krawittl 996). Up to 80% of patients achieve remission with a 
biochemical response occurring within three months and remission after years of 
treatment. The majority requires long-term treatment and of those who relapse after 
stopping treatment, remission is much more difficult to achieve the second time 
round. The treatment failure group consists of patients with established cirrhosis, 
those with disease onset at a young age, HLA B8 and DR 3 phenotype and those who 
present with disease of long duration pre-treatment. 
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TABLE: 11 
Treatment of Autoimmune Hepatitis 
(Czaja 1995, Krawitt 1996 and Van Den Berg 1998). 
TYPE OF MONOTHERAPY COMBINATION 
THERAPY THERAPY 
Initial Prednisone 20-30mg daily Prednisone 10-20mg daily and 
Azathioprine 50-100mg daily 
Maintenance Prednisone 5-15mg daily or Prednisone 5-10mg daily and 
Azathioprine 100-200mg daily at Azathioprine 50-100mg daily 
- 2mg/kg body weight 
lnvestigational Cyclosporin A* or Tacrolimus* Ursocholic acid and other 
orMMF* immunosuppresants 
*- Have been tried as first line therapy in steroid-resistant disease. 
MMF= Mycophenolate mofetil. 
Despite compliance, corticosteroid therapy has a failure rate of 9% and up to 13% 
have significant drug toxicity as to require early treatment withdrawal (Hegarty et al. 
1983 ). In those who fail to achieve permanent remission, cirrhosis occurs in 40% 
within ten years (Davis et al. 1984). Cyclosporin A (CYA) at 5-6mg/kg /day has 
shown favourable outcomes, particularly in inducing remission in steroid resistant 
AIH. However it still needs to be tested against prednisone in controlled clinical trails. 
It is therefore not established therapy and its significant side effects should be 
considered when starting treatment, which is potentially indefinite. Relapse after 
stopping CY A occurs in all patients (Hyams 1987, Faulds 1993). Tacrolimus has not 
been fully evaluated but initial results show biochemical improvement after three 
months of therapy, but this is associated with a deterioration in the renal functions 
(Van Thiel 1992). Ursodeoxycholic acid has been used in the treatment of patients 
with chronic viral hepatitis and has been shown to reduce serum aminotransferases. 
The theoretical advantages of using ursodeoxycholic acid in AIH include: 
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1. The choleretic effect that it has in displacing potentially hepatotoxic hydrophobic 
bile acids from hepatocytes (Galle et al. 1990). 
2. The prevention of ileal re-absorption of hydrophobic bile acids. 
3. Reduction of direct toxic injury by protecting the hepatocyte membrane (Poo et al. 
1992). 
4. Its immunomodulating effects that can alter the expression of class I HLA 
antigens on hepatocyte membranes and reduce cytotoxic T cell attack (Calmus et 
al. 1990). 
5. Its safety and low side effects profile (Ward et al. 1984). 
The other possible new treatment options include mycophenolate mofetil and 
rapamycin. However the place of these therapies in the management of AIH still 
needs to be established in randomised controlled trails. 
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CHAPTER 2: 
CHRONIC HEPATITIS AT GROOTE 
SCHUUR HOSPITAL: 1978-1996 
2:1 INTRODUCTION 
The spectrum of chronic hepatitis at Groote Schuur Hospital (GSH) was first 
described in 1980 by Poreh et al. who studied 54 patients who had been seen at GSH 
between 1964 and 1977 with clinical, biochemical and histological criteria for 
diagnosing chronic active hepatitis (CAH) as defined by the Fogarty International 
Conference on Standardization of Nomenclature, Diagnostic Criteria and Diagnostic 
Methodology of October 1974 (Leevy C et al. 1976). At this conference, CAH was 
defined as "a continuing inflammatory lesion of the liver with a potential to progress 
to more severe disease, including cirrhosis, to continue unchanged or to subside 
spontaneously with or without treatment." 
Each patient had a liver biopsy, antinuclear factor (ANF), smooth muscle antibody 
(SM), anti-mitochondrial antibody (AMA), LE cell preparations, biochemical, 
haematological and HBV surface antigen assays. On assessment, the male to female 
ratio was almost 1 and the physical examination was unhelpful in diagnosing chronic 
active hepatitis. ANF was positive in 39%, SM antibodies in 40%, LE cells in 34%, 
HBsAg in 39% and all were anti-mitochondrial antibody negative. In those who were 
HBsAg positive, 38% were also SM antibody positive, 20% and 30% positive for 
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ANF and LE cells respectively. No comment was made on the histological features 
and survival of these patients, but the histological criteria for diagnosis included 
round-cell infiltration involving the portal tracts with moderate or severe piece-meal 
necrosis of liver cells extending outward into the parenchyma from the limiting plate 
as defined at the Fogarty International Conference. 
Seggie et al. in 1979 described a subset of chronic hepatitis, that of methyldopa-
induced liver disease. They described 12 patients with severe symptomatic 
methyldopa related liver disease who had presented between 1967-1977 at GSH. 
Methyldopa had been introduced for the treatment of hypertension in the early 1960s 
(Irvine et al. 1962) and soon thereafter there was a plethora of published literature on 
its potential for hepatotoxicity (Elkington et al. 1969, Maddrey and Boitnott 1977). In 
75% of the patients described, illness occurred within 1-9 weeks of starting therapy (9 
of 12 patients) and in the other 25%, the drug had been received for 13 months, 15 
months and 7 years prior to experiencing any symptoms. A tender hepatomegaly and 
jaundice were frequent presentations and the histology ranged from mild fatty change, 
focal hepatocellular necrosis to massive hepatic necrosis. On withdrawal of the drug 
at presentation, 82% (9 of 11 patients) showed a rapid clinical improvement. Two 
patients died following a drug rechallenge by mistake resulting in a mortality of 
16.66%. In three patients, jaundice recurred within two weeks of accidental drug re-
exposure. The majority of the patients were female, 83.33% (10 of 12patients) giving 
a male to female ratio of 1 :5. 
The current study is a retrospective case file study looking at the various aetiologies 
of chronic hepatitis, clinical presentations, serologic and biochemical features. The 
treatments used and outcome in terms of prognosis, liver transplantation and death 
CHAPTER: 2 RESULTS AND DISCUSSION - 53 -
will be discussed. The available liver biopsy slides were reviewed blindly, graded and 
staged according to current criteria (Desmet 1994, Ishak et al. 1995). 
2:2 PATIENTS AND METHODS 
2:2.1 STUDY POPULATION 
The patients studied were seen at Groote Schuur Hospital between January 1978 and 
December 1996. These were primarily referrals from other hospitals or clinics and 
from private medical practitioners. The majority of the patients had been seen at the 
liver clinic at least once or had been assessed in the wards as referrals from other 
departments within GSH. 
2:2.2 EPIDEMIOLOGICAL INVESTIGATION 
A search of the computerized hospital records was done for the period January 
1978-June 97 using the diagnostic codes chronic hepatitis, chronic active hepatitis, 
drug-induced hepatitis, lupoid hepatitis and viral hepatitis. The search obtained 
2094 records. For inclusion into the study, the patients had to have had at least a 6 
months history of illness and satisfy the definition of chronic hepatitis as proposed 
by the International Working Party in 1995 (Figure 1, International Working Party 
1995). Alcohol or other alcohol-related diseases such as alcoholic pancreatitis were 
listed in 590 records. A further 1278 records were excluded following folder 
retrieval and analysis due to the following reasons: 
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REASONS FOR EXCLUSION FROM THE STUDY. 
A. Missing or untraceable files and wrongly recorded folder numbers. 
B. A diagnosis not fulfilling the current criteria for chronic hepatitis such as: 
1. Acute or fulminant HA V and HBV infection. 
2. Acute TB drugs hepatitis or acute poisoning with paracetamol, phenytoin and 
alcohol. 
3. Felty's syndrome. 
4. Congenital webs of the inferior vena cava and congenital hepatic fibrosis. 
5. Haemochromatosis or secondary iron overload. 
6. Primary biliary cirrhosis, primary sclerosing cholangitis and secondary biliary 
cirrhosis. 
7. Metastatic deposits to the Ii ver. 
8. Budd-Chiari syndrome. 
9. Sarcoidosis. 
10. Ischaemic liver damage. 
12. Septicaemic states. 
This left 226 files available for further study. The records were searched for 
information on: 
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1. Full blood count, INR and liver tests results at the initial presentation to hospital. 
2. AMA, SM antibodies, ANF, alpha feto protein and anti-LKM-1 antibodies. 
3. Details of liver histopathology. 
4. Other medical diagnosis. 
5. Duration of follow-up recorded. 
6. Therapy given or not given for a particular reason. 
7. Complications and the cause of death if recorded. 
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2:3 RESULTS 
2:3.1 DEMOGRAPHIC DATA AND CLINICAL FEATURES 
Of the 226 patients available for analysis, 55% (124 of 226 cases) were female and 
45% (102 of 226 cases) male giving a male: female ratio of 1:1 (Table 12). 
TABLE: 12 
Gender and racial distribution 
BY RACIAL GROUP WHOLE GROUP 
MALE FEMALE %OF GROUP MALE FEMALE 
COLOURED 34 59 41.2% 
WHITE 37 35 31.9% 102 124 
BLACK 26 25 22.6% 
INDIAN 5 5 4.4% 
Compared to the population demographics of the Western Cape from the 1996 
population census of South Africa, the patient distribution by race is remarkably 
similar (Figure 7). In the census, the Coloured population was 54.2%, Whites were 
20.8%, Blacks were 20.9% and the Indians were only 1 % of the population. 














W. CAPE STUDY GROUP 
lo BLACK •tNDIAN DWHITE CCOLOURED I 
- 56 -
W. CAPE - Data of the Western Cape population obtained from the South African 
population census of 1996. 
The ages at diagnosis of the study population had a uniform spread with a bimodal 
distribution curve on plotting. The age ranges were from as young as 3 years of age 
and the oldest patient was 78 years old. The mean age at diagnosis was 39.3 years 
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The various clinical features recorded during the first clinical assessment were 
documented. These are summarized in Table 13. 
TABLE: 13 
PRESENTING CLINICAL FEATURES 
CLINICAL FEATURE NUMBER OF %0FTOTAL 
PATIENTS PATIENTS 
Palpable liver. 111 49 
Ascites. 89 39 
Jaundice. 97 43 
Abdominal pain. 79 35 
Palpable spleen. 71 31 
Loss of weight. 61 27 
Malaise. 56 25 
Spider naevi. 43 19 
Haematemesis. 32 14 
Nausea and/or vomiting. 36 16 
Overt encephalopathy. 18 8 
Foetor hepaticus. 19 8 
Pruritis. 14 6 
Amenorrhoea. 17 of 124 women 14% of women 
Arthralgias. 10 4 
SBP/Fever. 13 6 
Testicular 7 of 102 men 7% of men 
atroJ!hr/Gl'.naecomastia. 
Abdominal striae. 5 2 
Tattoos/traditional 6 3 
scrarifications. 
Previous blood 6 3 
transfusions. 
Acne. 4 2 
Nose bleeds. 3 1 
No problems. 2 1 
SBP-Spontaneous bacterial peritonitis. 
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The most common mode of presentation was with one or more of the following: 
jaundice (43% ), ascites (39.4%) with a "palpable liver" (49% ). The precise size of 
the liver was not always recorded and so it is likely that in some instances the 
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"palpable liver" was the caudate lobe or the left lobe of liver rather than a truly 
enlarged liver (Di Bisceglie and Hoofnagle 1996). The common presentation was 
associated, to a lesser extent, with the presence of abdominal pain, a palpable spleen 
and significant loss of weight. 
The diagnostic categories used are as outlined in Table 14 and Figure 10. 
TABLE: 14. 
DIAGNOSTIC CATEGORIES 
DIAGNOSIS NUMBER OF %0FTOTAL 
CASES PATIENTS 
1. HBV CHRONIC HEPATITIS 75 33 
2. HCV CHRONIC HEPATITIS 25 11 
3. AUTOIMMUNE HEPATITIS 
(Positive immune markers) 51 23 
4. CRYPTOGENIC STEROID 
SENSITIVE CHRONIC HEPATITS 26 11 
(CRYP +) (Negative viral and immune 
markers) 
5. CRYPTOGENIC CHRONIC 
HEPATITIS (CRYP-) 41 18 
(Negative viral and immune markers, no 
steroids given or no response to steroids) 
6.DRUGS 8 4 
Methyldopa 6 3 
Carbamazipine 1 0.4 
Chlorpromazine 1 0.4 
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HBV - Hepatitis B virus chronic hepatitis, HCV - Hepatitis C chronic hepatitis, 
Am-Autoimmune hepatitis, CRYP (+)- Cryptogenic steroid sensitive chronic 
hepatitis, CRYP (-)- Cryptogenic chronic hepatitis, DRUGS- Drug-induced 
chronic hepatitis. 
2:3.2 LABORATORY INVESTIGATIONS 
No statistical difference could be shown among the patients when the biochemistry 
and haematology data at presentation were analysed. The mean values of the 
haematology and chemistry are summarized in Table 15. However there were 
differences in the biochemistry, haematology and ages at presentation when analysed 
by aetiology but these were not statistically significant. This is outlined in Table 16. 
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TABLE: 15 
Mean haematology and biochemistry values of the whole group 
HB wee PLT INR TP ALB TB ALP 




HB- haemoglobin, wee- white cell count, PL T- platelets, INR- international 
normalized ratio, TP- total protein, ALB- albumin, TB- total bilirubin, ALP- alkaline 
phosphatase, AST- aspartate aminotransferase, ALT- alanine aminotransferase, 
GGT- gamma-glutamyltranspeptidase. 
TABLE: 16 
Mean values by aetiology at presentation 
DIAGNOSIS INR TB TP ALB AST ALT ALP 
1. HBV 1.4 40 72 32 157 171 206 
2.HCV 1.4 72 77 37 120 149 194 
3. AIH 1.6 96 82 32 224 186 266 
4. CRYP + 1.6 85 73 32 300 264 360 
5. CRYP- 1.4 67 71 34 124 150 348 
6. DRUGS 1.6 73 81 36 85 90 280 
From Table 16, the sickest patients at admission when judged by the lowest albumin, 
highest AST/ALTffB and ALP appeared to be from the autoimmune hepatitis and the 
cryptogenic steroid sensitive chronic hepatitis groups. The diagnostic groups with the 
less severe disease at presentation when assessed by the highest total protein and 
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2:3.3 LIVER HISTOPATHOLOGY 
Sections of liver were available for analysis in 211 of the 266 patients (i.e. 93.4% of 
the patients). Slides could not be traced in 10 patients who had biopsies at other 
hospitals prior to referral to GSH. In 4 of the 16 patients with hepatocellular 
carcinoma, the diagnosis was made on the basis of a combination of ultrasound scan 
and/or CT scan abdomen, alpha feto-protein level and in 1 patient, a fine needle 
aspiration biopsy was done. All the slides were retrieved and reviewed blindly and 
without the knowledge of the clinical details by the author and Professor P Hall (PH), 
Department of Pathology University of Cape Town. The slides were scored for 
histological activity index (HAI) and stage of fibrosis using the Ishak system (Ishak et 
al. 1995, see Tables 6(a) and 6(b) pages 22, 23). A separate score for HAI using the 
Bedossa scoring system was also given with the intention of comparing two systems 
which assess the grade of disease (Bedossa et al. 1996, see Chapter 1 section 1:3.3 
page 20). The author did an initial score separately and then reviewed the slides with 
PH during which time a consensus score was agreed upon by both observers. Poor 
quality slides were restained or additional sections were made from the original 
biopsy blocks if these could be traced. These results are summarized in Figure 11 and 
analyzed in Figure 12 as the frequency of cirrhosis (i.e. presence of stage 5 or 6 
score) in each diagnostic group and also as a breakdown of the cirrhotic group (the 
120 patients with stage 5 or 6) by aetiology (Figure 13). 
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FIGURE: 13 
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The Bedossa and Ishak scoring systems are compared in Figure 15. The Ishak system 
has been previously discussed in Chapter 1 Section 1:3.3 and summarized in Tables 
6(a) and 6(b). The Bedossa system was proposed in 1996 by the French MET A VIR 
group for grading activity in chronic hepatitis C. A panel of 10 pathologists separately 
reviewed 363 chronic hepatitis C liver biopsies and a consensual algorithm on the 
grading of histological activity was established. In working out the algorithm, the 
consensus reached by the pathologists was that the intensity of piecemeal necrosis 
(PMN) was the major criterion that each one of them had used to decide on the 
severity of the grade. The lobular necrosis (LN) was not a major criterion but its 
intensity could be used to modulate the degree of activity. There was also a very 
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significant positive correlation between the severity of PMN and portal inflammation 
(p value< 0.00001). Portal inflammation itself was not thought to influence the 
assessment of the degree of activity and so is not scored in the Bedossa algorithm 
(Figure 14). This is of importance when looking at the correlation plot of Bedossa 
and Ishak grade scores in which cases with marked portal tract inflammation but less 
prominent PMN would have high Ishak scores but low Bedossa scores resulting in the 
rather wide scatter shown in Figure 15. Compared to the Ishak scoring protocol, the 
proposed Bedossa scheme is simpler and faster to score mainly because it uses fewer 
criteria for scoring. 
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FIGURE: 14 
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PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate; 3, severe; LN, lobular 
necrosis; 0, no or mild; 1, moderate; 2, severe; A, histological activity; 0, none; 1, 
mild; 2, moderate; 3, severe. 
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Figure 15 shows the correlation that was shown between the Bedossa score and the 
Ishak grade score. The Ishak scoring was done initially and the Bedossa score done 
next at the same assessment. The r-value was 0.7, showing a very significant 
correlation. 
FIGURE: 15 
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Figure 16 shows the changes in the stage of disease at diagnosis and the number of 
patients with cirrhosis during the entire period of the study. The patients with a stage 
of fibrosis ~ 5 (i.e. with cirrhosis) are plotted together with their trend lines. The trend 
line of the stage of disease shows no significant change and specifically, there is no 
improvement in the severity of disease at the time of diagnosis. In fact the stage of 
disease plot shows a tendency to a worse stage of disease at diagnosis. There were 
16 
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clearly more cirrhotic patients diagnosed with each year and this may be reflecting the 
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The number and types of biopsies done in this study cohort are summarized in Table 
17 and Figure 17. Most of the biopsies were done in the last 10 years of the study. 
TABLE: 17 
SUMMARY OF BIOPSIES DONE (1976-1996) 
TYPE OF BIOPSY 
PERIOD Transjugular Percutaneous Open Explanted Postmortem 
1976-1986 20 42 5 Nil 3 
% of total 29% 60% 7% NIL 4.3% 
1987-1996 25 98 9 6 4 
% of total 18% 69% 6% 4.2% 2.8% 
The postmortem biopsies were done 35 to 120 hours after death and as a result, the 
grading components were not always possible to score due to the presence of tissue 
autolysis on the liver sections. The explanted liver histology appears from 1988 with 
the onset of the liver transplant programme at Groote Schuur Hospital. The explanted 
liver histology is included under the open biopsies in Figure 17. 
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FIGURE: 17 
















• PC - Linear (T J) e OPEN PM --Linear (OPEN) - Linear (PM) 
TJ - Transjugular, PC - Percutaneous, PM - Postmortem. 
The only complication recorded in this series of biopsies was of biliary peritonitis. 
TQis occurred in one patient and was managed conservatively. The patient made a full 
recovery. This would give a complication rate of 0.47% with no deaths being 
recorded. From Table 17 and Figure 17, most patients were biopsed percutaneously. 
During the first 10 years of the study, a third of the patients (29%) had transjugular 
biopsies and this dropped to 18% in the last lOyears of the study with more 
percutaneuos biopsies being done. 
2000 
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2:3.4 VIRAL CHRONIC HEPATITIS 
2:3.4(a) HBV CHRONIC HEPATITIS 
There were 75 patients with chronic hepatitis due to HBV infection. 51 were male 
(68%) and 24 female (32%) giving a male: female ratio of2:1 . The ages at diagnosis 
showed a normal distribution curve and ranged from 3-67 years and the diagnosis was 
most frequent in the Coloured and Black populations (Figures 18, 19). 
FIGURE: 18 
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At diagnosis, HBsAg and HBeAg were recorded as positive in 96% (72 of 75 
patients) and 43% (32 of 75 patients) respectively. In 3 patients, only the HBeAg 
result was recorded in the folders. On immunohistochemistry studies of the biopsies, 
HBsAg was positive in 52.3% of the HBV biopsies (34 of 65 biopsies) and the 
HBcore antigen was positive in 16.9% (11 of 65 biopsies). 
The amount of alcohol consumption was poorly recorded in most patients. An 
assessment of the weekly alcohol use was clearly recorded in only 10 patients. No 
accurate comment is possible in this group as regards their pattern and degree of 
alcohol use. 
Interferon alpha (IFN) therapy was given in 6 patients of this group. The duration of 
therapy was 16 weeks. Four patients responded with loss of the HBeAg but one 
patient relapsed within a year. Four patients received corticosteroids, in two patients 
this was as part of steroid withdrawal therapy with IFN in 1989 and the other two 
patients received the treatment in 1981 as a trial of steroid therapy during episodes of 
raised transaminases. There were three patients who had lamuvidine. This was as part 
of a trial in two patients and in the third, it was given as monotherapy because IFN 
could not be used due to established cirrhosis with leukopaenia and 
thrombocytopaenia. 
The follow-up documented in months up to December 1996 is summarized in 
Table18. 
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TABLE: 18 
Follow-up of the HBV group 
NUMBER OF PATIENTS 
KNOWN TO BE ALIVE 13 
DEAD 23 
LOST FOLLOW-UP 39 
Less than 6months 20 
6 to 12 months 9 
More than 12 months 10 
- 73 -







The majority of patients in this group were lost to follow-up (52 % ) and in most of the 
patients, this occurred within 6 months of being diagnosed (26.7% ). 
2:3.4(b) HCV CHRONIC HEPATITIS 
25 patients had HCV infection with 14 males (56%) and 11 females (44% ). The 
male: female ratio was 1.3: 1. The disease was most frequent in the White and 
Coloured populations (44% and 32% of the HCV group respectively), with age 
ranges of 14-73 years (Figures 20, 21). There were no cases from the Indian 
population and there was a tendency for the older age group to be affected, with the 
age distribution curve showing a significant skew to the right. 
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The results ofHCV PCR testing could be obtained for 16 of the 25 patients and the 
genotypes recorded are shown in Figure 22. 
CHAPTER: 2 RESULTS AND DISCUSSION - 75 -
FIGURE: 22 
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There were five patients who received IFN therapy. Treatment was given over a 
period of 24-52 weeks. In one patient the treatment was part of a trial but the follow-
up is not available. In the remaining four patients, there was no response to the 
treatment. One patient had a liver transplant but died two years later from 
complications of colon resection surgery that was unrelated to the transplant. Steroids 
were used in three patients, in one patient this was for co-existing haemolytic anemia 
and in the other two patients steroids were given as a trial of therapy during 1982 and 
1989 for severe hepatitis. The ANF was positive in two patients in titres of 1 : 10 and 
1 :2500. One patient was SM antibody positive with a titre of 1 :60. 
The history of alcohol consumption was again poorly recorded and an assessment of 
the intake could be made in only two patients and so this data is ignored. 
The duration of follow-up until December 1996 is summarised in Table 19. 
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TABLE: 19 
Follow-up of the HCV group 
NUMBER OF PATIENTS 
KNOWN TO BE ALIVE 6 
DEAD 4 
LOST FOLLOW-UP 15 
Less than 6 months 7 
6 to 12 months 2 
More than 12 months 6 
2:3.5 DRUG-INDUCED CHRONIC HEPATITIS 
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This group was very small with only eight patients satisfying the criteria for drug-
induced chronic hepatitis. There were 3 males and 5 females giving a male: female 
ratio of 1:2. The age ranges at diagnosis were 21-68 years with a tendency for the 
older populations to be affected although the numbers are too small to really support 
this (Figures 23, 24). 
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Alpha-methlydopa was incriminated in six of the cases, carbamazepine and 
chlorpromazine in one case each. The alcohol intake was poorly recorded and the 
follow-up done is summarized in Table 20. 
TABLE: 20 
Follow-up of the drug-induced hepatitis group 
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 0 0 
DEAD 1 12.S 
LOST FOLLOW-UP 7 87.S 
Less than 6 months 2 25 
6 to 12 months 1 12.5 
More than 12 months 4 50 
2:3.6 AUTOIMMUNE HEPATITIS 
There were 51 patients with AIH. 15. 7 % were male (8 of 51 patients) and 84.6 % 
were female (43 of 51 patients) giving a male: female ratio of 1:6. The diagnosis was 
most frequent in the Coloured and White populations and rare in the Black and Indian 
communities (Figures 25, 26). 













ID BLACK B WHITE O INDIAN O COLOURED I 
AIH AGE PROFILE 
- 79-
~ 12 -+:--.,...,.:~.:..;;.,,,~--..,,.~=.:,.;:;.....;....;;...;;~~~---,:~...,,..,,........,.,.::...::.:;... ____ ...:.:.:;.;.....,,._.,,. 
z 
UJ 
j:: 10 -+,,;;-.......;f---~-_.,.... ........ -...:-,....~~a:...........,._..,....... _ ___.._.......;._,;.:;;;:...............,..~--,.....;;..::.:: 
<( 
Q. 





~ i 4T."if---;~ ~-,=~:.,,.-.;.,.::.~-.-:,,..;;.;;;,;;.;,._,..---,,~~_._~_.._,.......J.___"--____ _._=.,....~ 
0 10 20 30 40 50 60 70 80 90 
AGE RANGES 
CHAPTER: 2 RESULTS AND DISCUSSION - 80 -
The age ranges at diagnosis were 9-78 years. The ANF was positive in 36 patients 
(71 % ); SM in 27 patients (53%) and 13 patients (25%) had both ANF and SM 
positive. Only one patient (2%) was positive for the LKM-1 antibody (see Table 29). 
The mainstay of treatment was steroids on their own in 29 patients (56% ), steroids 
and azathioprine combination was used in 15 patients (29% ), azathioprine alone in 1 
patient (2%) and no treatment was given in 6 patients (12% ). Only one patient 
received IFN therapy following a false positive HCV antibody test and she 
deteriorated on the treatment. The follow-up recorded is summarized in Table 21. 
TABLE: 21 
Follow-up of the AIU group 
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 14 27 
DEAD 14 27 
LOST FOLLOW-UP 23 44 
Less than 6 months 6 12 
6 to 12 months 0 0 
More than 12 months 17 33 
The disease associations recorded included the following: HCV co-infection in two 
patients. In one of them the HCV results turned out to be a false positive. Genetic 
haemochromatosis was recorded in one patient who was a heterozygote for the 
C282Y mutation. PBC overlap syndrome was recorded in 2 patients but the histology 
was suggestive in one patient only. Inflammatory bowel disease was reported in 2 
patients and discoid lupus erythematosus in one patient. 
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2:3.7(a) CRYPTOGENIC STEROID SENSITIVE CHRONIC HEPATITIS 
There were 26 patients in this group with 6 males (23%) and 20 female (77%) giving 
a male: female ratio of 1:3.The disease was most common in the White and Coloured 
populations, comprising 48% and 32% of the group respectively. The age ranges at 
diagnosis were between 3 and 70 years (Figures 27, 28). 
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All the patients were treated with steroids with or without azathioprine in 
combination. Most patients, 69% (18 of26 patients) were treated with steroids alone. 
In 31 % (8 of26 patients) treatment was with steroids and azathioprine in combination 
and only one patient received IFN due to a false positive HCV antibody. One patient 
was transplanted and is still alive. The follow-up periods recorded are summarized in 
Table 22. 
TABLE: 22 
Follow-up of the cryptogenic steroid sensitive chronic hepatitis group 
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 13 50 
DEAD 7 27 
LOST FOLLOW-UP 7 27 
Less than 6 months 2 8 
6 to 12 months 1 4 
More than 12 months 4 16 
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2:3.7(b) CRYPTOGENIC CHRONIC HEPATITIS 
This group consists of those patients who were negative for viral markers (HBsAg, 
HBeAg, HBs antibody, HCV antibody and PCR, immunohistochemistry for HBsAg 
and HBcore Ag) and autoimmune markers (AMA, anti-LKM-1 antibody, ANF and 
SM antibody). They did not respond to a steroid course or were not given any steroids 
at all. There were 41 patients in this group with 21 males and 20 females giving a 
male: female ratio of 1:1 . The age ranges at diagnosis were from 10-76 years and the 
diagnosis was equally frequent in all the racial groups (Figures 29, 30) . 
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FIGURE: 30 
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Of the 41 patients, only three had a trial of steroid therapy. The lengths of the 
treatment courses were 3 to 7 months and one patient had both steroids and 
azathioprine over 7 months. None of the patients had a clinical response to the 
treatment given. Four patients had liver transplants done and two had documented 
HCC. The follow-up recorded in the patients is summarized in Table 23 . 
TABLE: 23 
Follow-up of the cryptogenic chronic hepatitis group 
100 
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 3 7 
DEAD 7 17 
LOST FOLLOW-UP 31 76 
Less than 6 months 18 44 
6 to 12 months 7 17 
More than 12 months 6 15 
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2:3.8 HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS 
Hepatocellular carcinoma (HCC) was documented in 16 of the 226 patients in the 
study and this constitutes 7% of the study group. There were 12 males and 4 females 
giving a male: female ratio of 3:1 . The tumour was common in the Black population 
(50% of the HCC patients) and was most frequent in the Black males who were 38% 
of the HCC cases (6 of 16 patients). The age ranges at diagnosis were 18 to 63 years 
(Figures 31, 32). 
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FIGURE: 32 
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Analysis by aetiology shows that HBV was the most frequent cause and there were no 
cases from the Alli and cryptogenic steroid responsive chronic hepatitis groups 
(Figure 33). 
FIGURE: 33 
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HBV - 81 %, BCV - 6%, Am - 0%, Cryptogenic steroid sensitive chronic 
hepatitis - 0%, Drug-induced chronic hepatitis - 0%, Cryptogenic chronic 
hepatitis - 13%. 
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There were two patients who underwent liver resection, another two had 
chemotherapy and one patient had a liver transplant and the HCC was an unexpected 
finding in the explanted liver. The follow-up in these patients is summarized in Table 
24 and the histopathology of HCC is illustrated in Appendix C. 
TABLE: 24 
Follow-up of the HCC group 
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 1 6 
DEAD 6 38 
LOST FOLLOW-UP 9 56 
Less than 6 months 6 38 
6 to 12 months 0 0 
More than 12 months 3 19 
2:3.9 OTHER ASSOCIATIONS WITH HBV CHRONIC HEPATITIS 
There were 11 patients with chronic HBV infection who had some other associated 
diseases that were not observed in the other diagnostic groups. Six patients (55% of 
the group) had haematological malignancies. These were non-Hodgkin's lymphoma in 
4 patients, chronic myeloid leukemia and acute lymphoblastic leukemia in the other 2 
patients. This was an interesting observation, which may reflect HBV infections that 
were acquired during the treatment of the malignancies since in all cases the 
malignancy preceded the diagnosis of HBV infection. There are case reports in the 
literature of a possible association between HCV and Non-Hodgkin's lymphoma but 
other workers (Pazzalo et al. 1994, Ferri et al. 1994, and Ellenrieder et al. 1998) have 
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not substantiated this. The associations documented are summarized in Table 25 and 
Figure 34. 
TABLE: 25 
Disease associations with HBV chronic hepatitis 
DISEASE NUMBER 
HAEMATOLOGICAL 6 
Chronic myeloid leukemia 1 
Acute lymphoblastic leukemia 1 
Non-Hodgkin's lymphoma 4 
POLY ARTERITIS NODOSA 1 
CHURG-STRAUSS SYNDROME 1 
CROHNS' COLITIS 1 
NEPHROTIC SYNDROME 1 
PAN and Nephrotic syndrome 1 
FIGURE: 34 
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PAN- Polyarteritis nodosa, IBD- Inflammatory bowel disease. 
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The follow-up record available in these patients is recorded in Table 26. 
TABLE: 26 
Follow-up of the HBV disease associations group 
- 89 -
NUMBER OF PATIENTS % OF TOTAL GROUP 
KNOWN TO BE ALIVE 3 27 
DEAD 2 18 
LOST FOLLOW-UP 6 55 
Less than 6 months 2 18 
6 to 12 months 1 9 
More than 12 months 3 27 
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2:4 DISCUSSION 
The study population consists of patients with chronic hepatitis in the setting of 
strictly defined criteria (International Working Party 1995). As a result there are a 
number of patients who could not be included into the study due to the non-
availability of hospital folders, wrong diagnostic codes or too short a period from the 
onset of illness (see section 2:2.2, epidemiological investigation). There will 
therefore be cases that might have fulfilled the study criteria but are not included in 
this study cohort. 
2:4.1 DEMOGRAPHIC DATA AND CLINICAL FEATURES 
The recorded clinical features would suggest a late presentation by these patients 
(Table 13). The presence of jaundice, splenomegaly, loss of weight and ascites are in 
keeping with advanced liver disease (Di Bisceglie and Hoofnagle 1996). These 
features were very prominent in these patients. A palpable liver was a frequent 
recording although in most of the cases the precise liver size was not recorded. It is 
likely that in some cases this merely reflected the presence of a palpable left lobe of 
liver or a caudate lobe in a cirrhotic liver rather than a definitely enlarged liver. A 
proper assessment of the incidence of clinical problems such as amenorrhoea, acne, 
striae and pruritis in this population is not possible due to the poor recording of these 
findings at clinical visits. The absence of proper recording of the history of alcohol 
use means that the study is unable to assess the impact that alcohol would have made 
on the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma. 
Alcohol intake has been shown to accelerate the progression to cirrhosis in HCV 
(Wiley et al. 1998) and to increase the risk to developing HCC in chronic HBV 
infection (Mohamed et al. 1992). 
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The bimodal distribution of the age at diagnosis of the whole group shows two small 
peaks, the first in the third to fourth decades and the second the sixth to seventh 
decades (Figures 8, 9). The first peak would relate to the predominance of AIH in the 
early years (Figure 26) and the late peak is explained by the higher incidence of 
chronic viral hepatitis in these decades (Figures 18, 20). 
The predominance of HBV chronic hepatitis is not surprising, as this is a common 
infection in Southern Africa with a reported 76% prevalence of positive HBV makers 
in South Africa (Kiire 1990, Kew 1992). The cryptogenic chronic hepatitis group i.e. 
(negative viral and autoimmune markers, no steroids given or no response to steroids) 
was significant, comprising 18% of the study group. This group was largely made up 
of patients who did not receive any steroids. Only 3 of the 41 patients received steroid 
therapy over periods of three to seven months, with one patients receiving both 
steroids and azathioprine without any clinical or biochemical response. The size of 
this group can be partly explained by the lack of HVC testing in most of the patients, 
as this may be a significant cause of cirrhosis in this setting (Jeffers et al. 1992). Only 
39% (16 of the 41 patients) were tested for the HCV antibody with only 2 of them 
having both antibody and PCR testing. The low use of a trial of steroids also raises the 
possibility that some of the patients may indeed have been steroid responsive. There is 
also the possibility of there having been a drug aetiology that was missed in the 
history, as the use of a drug was not consistently recorded. Lastly the possibility of an 
unknown viral cause is a possibility worth considering. 
The biochemistry and haematology profiles were not helpful in separating the patient 
groups by aetiology as most presented with advanced disease on the whole as shown 
by the high incidence of established cirrhosis at diagnosis (Figure 13). The 
biochemical abnormalities showed the pattern of the ALT being somewhat higher 
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than the AST (Table 16) except in the AIH and cryptogenic steroid responsive group 
who seemed to have slightly worse parameters (Williams and Hoofnagle 1996). The 
follow-up periods achieved differed markedly in the different diagnostic groups. This 
is summarized in Table 27. 
TABLE: 27 
Follow-up of the whole study group 
NUMBER OF PATIENTS % OF WHOLE GROUP 
KNOWN TO BE ALIVE 48 21 
DEAD 56 25 
LOST FOLLOW-UP 122 54 
Less than 6 months 56 25 
6 to 12 months 19 8 
More than 12 months 47 21 
When compared to the follow-up in each diagnostic group, the best follow-up was in 
those patients in whom treatment was available and in whom regular monitoring was 
done i.e. the AIH, cryptogenic steroid responsive and the liver transplant patients. The 
loss of follow-up was highest in the HBV and HCV patients where disease modifying 
treatments (IFN and lamuvidine) were not available until after 1991. From Table 27, 
more than half of the group (54%) was lost to follow-up at GSH and this occurred 
within 6 to 12 months of diagnosis. However some of the loss in follow-up can be 
attributed to the discharge of patients back to the referring hospitals since the Liver 
Clinic at GSH serves areas other than the Western Cape region. 
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2:4.2 HISTOPATHOLOGY 
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The high incidence of cirrhosis at the first clinical presentation is a major indicator of 
the late presentation that occurred. When the presenting stage scores of ~5 for 
biopsies (see Table 6(a) page 22) in each year are plotted over the 21 year period, it is 
interesting to note that the stage score at diagnosis and initial presentation did not 
improve but showed a slight worsening from 5.5 to 6 (Figure 16). The number of 
cirrhotic patients i.e. Ishak stage score of ~5, showed a steady increase over the 
period. This may be a reflection of an increased biopsy rate as shown in Table 17 and 
therefore an increased rate of diagnosis of those patients who were cirrhotic. These 
changes show that there was no improvement in the time from illness to diagnosis 
over the study period i.e. the patients on average still are referred late with advanced 
disease and invariably with established liver fibrosis. The correlation that was shown 
between the Bedossa and Ishak grade scores shows that the simpler method does give 
the same information as the more complex and rarely used system. The correlation 
obtained could also be due to the fact that both scores were done at the same 
histological assessment resulting in a tendency for the initial Ishak score to influence 
the scores given for the Bedossa assessment. Also the fact the author was taught liver 
histopathology assessment by the reviewing pathologist would have increased the 
tendency for agreement in the scoring process. On average the disagreement in the 
scores was by one or two points during the combined review of the slides. The points 
of disagreement would then be reviewed and a consensus score agreed upon. In spite 
of the good correlation between the two systems, there is a fairly wide scatter in 
values i.e. a grade score of 14 would correlate with a Bedossa score of 1 or 2. This is 
explained by the absence of a portal inflammation score in the Bedossa system. It 
means therefore that those sections which had prominent portal inflammation and less 
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marked piecemeal necrosis had higher scores on the Ishak system but this would not 
reflected in the Bedossa score which does not score portal inflammation. 
The liver biopsy practice did change during the study period. In the first 10 years of 
the study, 30% of biopsies were by the trans jugular route but this reduced to less than 
20%, this in spite of more trans jugular biopsies per year being done. This is explained 
in part by: 
(a) The availability of a safer and easier to use Menghini needle (Hepafix needle) 
resulting in more percutaneous biopsies being done. 
(b) The use of ultrasound scan guided percutaneous plugged biopsies by the 
Radiology department in the presence of coagulation disorders. The biopsy tract 
is plugged with 2ml of gelatin before the Tru-Cut biopsy needle is withdrawn. 
Using this procedure, patients who previously would have undergone transjugular 
biopsies can be biopsed in a safe manner and a shorter operating time. 
The postmortem biopsies were not very helpful due to tissue autolysis. This is due to 
the fact that all the postmortem tissues were obtained during the routine postmortem 
study, which in all the cases was after 35 hours. 
2:4.3 HBV CHRONIC HEPATITIS, DISEASES ASSOCIATED WITH HBV, 
HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS 
HBV chronic hepatitis and hepatocellular carcinomas were most prevalent in the male 
gender i.e. 81 % of the HCC were associated with HBV infection and the male: 
female ratio in the HCC group was 3:1 (Figure 33). This association has been shown 
in China and the Far East particularly (Lai C et al. 1987, Lok 1988) and studies from 
Southern Africa also show a male preponderance (Kew 1988). The explanations for 
this include: the higher carrier rates of HBV in males, the greater use of alcohol and 
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smoking in males (Lam 1982, Lai C 1987), greater exposure to chemical carcinogens 
in the work place, differences in the rates of metabolism of chemical carcinogens such 
as aflatoxins between the sexes (Linsell 1984) and a possible permissive role that the 
male hormonal milieu may have on HCC carcinogenesis (Kew 1996). Alcohol could 
also act as a promoter or a co-carcinogen and by inducing the hepatic microsomal 
P450-dependent biotransformation system, could produce reactive metabolites from 
ingested chemicals resulting in the formation of carcinogens (Lieber 1982). It is also 
interesting to note that although the cryptogenic steroid sensitive hepatitis and AIH 
groups had high incidences of cirrhosis at presentation, 60% and 46% respectively, 
none of them developed HCC during the follow-up period. This is very significant 
taking into account the fact that they had the longest periods of follow-up. The impact 
of alcohol unfortunately cannot be assessed in this study and a prospective study 
would be more appropriate to obtain such information. 
The age distribution curve of the HBV chronic hepatitis group does not take into 
account the young patients who are diagnosed and treated at the Red Cross Children's 
Hospital in the Western Cape. It would be expected that if these were included, there 
might be a small peak at around 10 to 20 years. The racial preponderance in the 
Coloured population most likely reflects the population demographics of the Western 
Cape where 54.2% of the population is Coloured (South African census 1996, Figure 
7). 
Only 6 patients in the study received IFN during the follow-up period. A sustained 
response was obtained in 3 patients and one patient responded but relapsed within one 
year. The other three patients did not respond at all. The current use of IFN therapy in 
chronic HBV can not be assessed by this study since regular use of interferon began 
after 1992, initially as part of drug trials. A study specifically designed to assess the 
CHAPTER: 2 RESULTS AND DISCUSSION 
efficacy of IFN therapy in HBV chronic hepatitis in South Africa needs to be 
undertaken. 
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HBV immunohistochemistry on the liver biopsy was valuable in one patient to 
achieve a diagnosis. In this patient, HBV infection was only proven on the liver 
histology studies of the explanted liver following liver transplantation for cryptogenic 
cirrhosis. The diagnosis before liver transplantation was cryptogenic chronic hepatitis. 
The serological makers for HBV infection had been negative in the serum and there 
had been no liver biopsy pre-transplantation due to the presence of a small and 
nodular liver on ultrasound scanning, deranged clotting and ascites. However in this 
series of biopsies, the HBsAg was positive in 52.3% of liver biopsies and the HBcore 
antigen in only 16.9%. The question does arise therefore of how many of the 
crytogenic chronic hepatitis group may fall into this category in spite of having 
negative serological markers for known viral infections. 
Chronic HBV infection was associated with other diseases and these were mostly 
haematological (55%) but also polyarteritis nodosa (PAN), churg-strauss syndrome, 
crohn's colitis and the nephrotic syndrome (NS). The associations with the NS and 
PAN are well documented (Lai KN 1987, Guillevin et al. 1992). The nephrotic 
syndrome occurs in less than 1 % of adults and is associated with active viral 
replication. The histological lesion in the kidney is that of membranous or membrano-
proliferative glomerulonephritis. These patients tend to have a good response to INF 
therapy. None of the patients in this group received IFN therapy. The pathogenesis of 
polyarteritis nodosa is not clear and it tends to be associated with the Churg-Strauss 
syndrome. It is characterized by the inflammation of medium-sized arteries and 
presents with severe hypertension, renal failure, and asthma with ischaemic events to 
various organs. These may present as stroke, ischaemia of the gut, a mononueritis 
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multiplex and acalculous cholecystitis. In these patients the diagnosis of PAN was 
made on the basis of renal biopsy, muscle and nerve biopsy, peripheral neuropathy 
and the histology of resected ischaemic bowel. Haematological malignancies are not 
reported in the literature as associations of chronic HBV infection although non-
Hodgkin's lymphoma has been associated with chronic HCV infection (Ferri 1994, 
Ellenrieder 1998). The association of HBV infection with chronic myeloid leukemia 
(1 of 6 patients), acute lymphoblastic leukemia (1 of 6 patients) and non-Hodgkin's 
lymphoma (4 of 6 patients) in this group is not clear. The association could be entirely 
coincidental as the number involved is small. The other plausible explanation is that 
the HBV infection was picked up during treatment for the haematological 
malignancy. This could occur through blood products or re-use of blood lancets used 
for finger-prick haemoglobin meters and glucometers. An outbreak of acute HBV 
infections did occur in the Haematology Department at GSH previously, which was 
traced to the re-use of blood lancets (unpublished observation). The presence of 
Crohn's colitis (1 patient) in this group is likely coincidental considering the 
significant incidence if inflammatory bowel disease in the Western Cape (Wright et al 
1986). 
2:4.4 HCV CHRONIC HEPATITIS 
This form of chronic hepatitis was most prevalent in the White and Coloured races 
and it is interesting to note that of the White population, 4 patients (16% of the HCV 
group or 44% of the White patients with HCV infection i.e. 4/9 white patients) were 
Italian immigrants living in the Western Cape. The presence of immigrants from 
Europe must have influenced the HCV genotype incidence (Figure 22) which shows 
that type 1 genotype was most frequent at 37%, types 2 and 4 at 25%, type 5 with a 
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low presence of 12 % and no type 3 present in the study cohort. The corresponding 
figures quoted for blood donors in the Western Cape in 1996 show a predominance of 
type 5 at 28%, type 1 at 20%, type 3 at 12%, type 2 at 8% and there was no type 4 
detected. The genotype could not be determined in 12 % of the blood donors (Voigt et 
al. 1996). An earlier study in 1995 using serum samples from around South Africa 
had also shown that type 5 was most prevalent, occurring in 40% of the group, type 1 
in 33%; and types 2, 3, and 4 occurring in 13.8, 7.7 and 2.3% respectively. In 3.8% 
of these patients the genotype could not be determined (Smuts and Kannemeyer 
1995). There was a history of a previous blood transfusion in 6 patients and 3 had 
tattoos suggesting the possible sources of infection in those patients. The population 
group was older with a mean age of 51 years making this the diagnostic group with 
the oldest patients (Table 16). 
None of the patients with HCV chronic hepatitis who received IFN therapy 
responded. This is summarized in Table 28. 
TABLE: 28 
IFN treatment in the HCV patients 
Genotype IFN dose per week Year of treatment Duration Outcome 
1 3Mu three times 1992 16 weeks No response, transplanted 
2 2.5Mu three times 1993 24 weeks No response 
2 3Mu three times 1992 24 weeks No response and IFN 
stopped due to side-effects 
5 3Mu three times 1995 52 weeks No response 
Mu - million units, IFN - interferon. 
The response of genotype 1 to interferon is known to be poor. Genotypes 2 and 3 have 
a better response to INF therapy. In the patients under discussion, the two patients 
CHAPTER: 2 RESULTS AND DISCUSSION - 99 -
with genotype 2 received treatment for standard recommended duration. One patient 
had 2.5 million units due to the presence of clinical depression. According to the 
current recommendations, their therapy would have been stopped once they had 
shown no biochemical response within three months of treatment (National Institutes 
of Health consensus statement 1997). The use of a longer duration of treatment has 
been shown to improve the sustained remission rate in those who respond to IFN but 
not the response rate (National Institutes of Health 1997, Alberti et al. 1996, and Par 
et al. 1998). The patient with the genotype 5 infection would according to the current 
knowledge and practice, not be expected to respond with prolonged treatment and the 
treatment would have been stopped after three months as well. The two patients who 
were ANF positive did not receive any specific therapy. The patient who was SM 
antibody positive had an autoimmune haemolytic anaemia for which a splenectomy 
was done in 1989. This patient was also treated with steroids for the haemolytic 
anemia. 
2:4.5 DRUG-INDUCED CHRONIC HEPATITIS 
This diagnostic group was the smallest and so it is difficult to make any definite 
deductions from the data of these patients. The major factor relating to why this group 
was disproportionately small is the poor recording of the drug histories of the majority 
of the patients. It is plausible that some of the cryptogenic chronic hepatitis group 
patients could be cases of drug-induced hepatitis. There were also cases that had 
possible drug aetiologies but were not biopsed because of clinical improvement and 
so could not be included in the study. The older hypertensive patients who reacted to 
methyldopa explain the bimodal distribution of the group and the other peak is due to 
the younger patients who reacted to other drugs (Figure 23). 
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A diagnosis of autoimmune hepatitis (AIH) was made in 23% of the study patients. 
The diagnosis was most frequent in the female gender with a male: female ratio of 1:6 
as described elsewhere (Czaja 1984). By definition, these patients would be mostly 
type 1 AIH because they were diagnosed on the basis of either a positive ANF, SM 
antibody or the presence of both antibodies (see Table 4 page 18). Only one patient 
had a positive LKM-1 antibody that is specific for type 2 AIH. From table 4, the only 
way to separate type 2 AIH from type 3 AIH immunologically would be by testing 
for the soluble liver antigen in those patients who were only positive for the SM 
antibody and negative for ANF. Although type 3 AIH can have a positive ANF, the 
incidence is extremely low at a rate of less than 5%. There were 14 patients who were 
only SM antibody positive and could potentially have type 3 AIH. The patients who 
were both ANF and SM antibody positive and those who were only ANF positive are 
type 1 AIH by definition. The immunological profiles of these patients and their 
probable AIH subtype are summarized in Table 29. 
TABLE: 29 
Immunology profiles of the AIH group 
POTEINTIAL AIH SUBTYPE 
ANTIBODY TEST TYPEl TYPE2 TYPE3 % OF GROUP 
LKM-1 1 2 
SM+ANF 13 25.5 
ANFONLY 23 45.1 
SM ONLY 14 27.5 
Soluble Liver Antigen NOT AVAILABLE 
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From Table 29, the diagnostic label of AIH subtype 1 could be assigned to 36 of the 
51 patients (70.6%) i.e. those ANF, SM and ANF positive; AIH subtype 2 to only 
I patient (2%) i.e. anti-LKM-1 positive. The SM only positive patients are potentially 
AIH subtype 3. They were 27.5% of the patient group (14 of 51 patients). Further 
differentiation would have been possible if soluble liver antigen antibody studies were 
done. 
The possibility that this group of patients may contain some patients who fit the 
diagnostic criteria for type 3 AIH is also suggested by the presence of three peaks on 
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explained by the presence of type 3 AIH in this group of patients. Type 3 AIH has an 
incidence peak around the third and fifth decades. 
The Coloured community of the Western Cape has a high incidence of autoimmune 
diseases such as rheumatoid arthritis and systemic lupus erythematosus. The 
associated high incidence of AIH in this population would therefore not be a surprise. 
A study emanating from this work is planned to investigate the HLA status and other 
features of the autoimmune hepatitis and cryptogenic steroid responsive groups as this 
would also help to classify the patients into autoimmune subtypes. As a group the 
AIH patients had the best follow-up and of those who were subsequently lost, this 
happened after more than 12 months (see Table 21). This was clearly due to the 
availability of treatment and the required follow-up needed to adjust steroid and 
azathioprine doses. 
In most of the patients (56% or 29 of the 51 cases) disease control was achieved with 
steroids alone but it is significant to note that 29 % (15 of the 51 cases) of the patients 
required combination treatment with azathioprine to achieve biochemical control of 
the disease. There was one patient who received IFN therapy in 1992 and had a 
marked clinical deterioration over 12 weeks of treatment. INF was stopped and 
prednisone was started with a good clinical response. The repeat HVC studies done 2 
years later in 1994 were negative. Only one patient has a record of a persistently 
positive HCV antibody and PCR with a positive ANF. She had no IFN given but was 
treated with steroids and azathioprine successfully. There was one patient who had 
genetic haemochromatosis and was heterozygote for the C282Y mutation. She was 
treated successfully with regular venesections, steroids and azathioprine combination. 
In the two patients who had the diagnostic label of AIH with PBC overlap, 1 had a 
suggestive histology with paucity of bile ducts and a positive AMA of 1: 40 titre. The 
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other patient's histopathology was not suggestive although there was marked 
cholestasis. 
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2:4.7 CRYPTOGENIC STEROID RESPONSIVE CHRONIC HEPATITIS 
This is a group of particular interest due to its many similarities to the autoantibody 
positive AIH in spite of the absence of serological markers. The points of significance 
were: 
1. The similar racial incidence profile. 
2. The similar female gender preponderance although this was half of that observed 
in the AIH i.e. 1:3 and 1:6 respectively. 
3. A similar clinical response to corticosteroids as well as the use of azathioprine. 
There was a need for azathioprine in 31 % of this group and 29% in the AIH 
group. 
4. The age distribution plot showed a profile similar to that of classic type 1 AIH 
with two incidence peaks at 5 - 20 years and 40 - 60 years (Figure 28). 
This diagnostic group raises a number of questions about the diagnosis of 
autoimmune hepatitis in the Western Cape. The possibility that there are other 
immune markers that are present and can help to tease apart this group further arises 
since the mixed ancestry population in the Western Cape consists of a heterogeneous 
gene pool. This is expressed in the high incidence of rheumatoid arthritis and systemic 
lupus erythematosus in this population group. The presence of such a genetic 
predisposition can be better assessed through HLA studies in the patients with 
autoimmune liver disease. 
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The size of this group might have been reduced if all of them had had HCV studies 
and a more thorough history search made for a possible drug aetiology for the 
cryptogenic cirrhosis. 
2:4.8 CRYPTOGENIC CHRONIC HEPATITIS 
This patient group was very different from the AIH and cryptogenic steroid 
responsive groups. The incidence in all the major racial groups was virtually the same 
and the sexes were equally affected. These patients also showed a tendency to 
developing hepatocelluar carcinoma while no HCC occurred in the AIH and 
cryptogenic steroid responsive groups. They also comprised 31 % of the patients with 
liver transplants (4 of 13 patients) which was the same as the latter two groups 
combined (see Figure 37, Chapter 3). 
Clearly the issues for debate on these patients again are: 
1. How many could have been a drug aetiology that was missed? This is impossible 
to exclude because the drug history is poorly recorded if at all. 
2. How many could have been a missed viral aetiology due to HCV or HBV 
infections. Only 16 of the 41 patients (39%) had an HCV antibody test done and 
in only 2 of these was a PCR test done as well. 
As a result of this study a number of observations and questions arise. It is clear that 
the AIH group at GSH is very heterogeneous and requires further study. A follow-up 
study of this group is planned to address the issues of: 
1. The subtypes of AIH. 
2. Further immunological and viral characterization of the cryptogenic steroid 
sensitive and the cryptogenic chronic hepatitis groups. 
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CHAPTER 3: 
MANAGEMENT OF CHRONIC HEPATITIS 
AT GROOTE SCHUUR HOSPITAL 
3:1 MEDICAL THERAPY 
The complications of chronic liver disease include cirrhosis with portal hypertension 
in association with ascites and oesophageal varices, infections (particularly 
spontaneous bacterial peritonitis), osteoporosis and complications of the treatments 
used to treat or control the primary liver disease. The treatment related complications 
include steroid-induced diabetes mellitus, osteoporosis and infections. 
The available treatments that would qualify as "disease modifying therapies" at the 
moment are: 
1. Steroids and azathioprine in the treatment of autoimmune hepatitis. The use of 
immunosuppression allows for the control of inflammation and retards the 
tendency to progress to cirrhosis. 
2. Interferon alfa alone or in combination with ribavirin. The use of combination 
therapy has now been shown to improve the success rate in the treatment of 
chronic hepatitis C infection (Davis et al. 1998, Reichard et al. 1998, 
McHutchinson et al. 1998). Studies have also shown that responders to interferon 
therapy have a lower incidence of developing hepatocellular carcinoma 
(Nishiguchi et al. 1995, Harper and Dienstag 1996, Kasahara et al. 1998). 
3. Lamivudine in the treatment of HBV infection with or without a liver transplant. 
4. Liver transplantation for end stage liver failure. 
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Chronic viral hepatitis therapy 
The early management of chronic viral hepatitis at Groote Schuur Hospital was 
primarily the management of the complications of chronic liver disease. The 
availability of interferon has meant the improved referral of the HBV and HCV cases 
from the Blood Transfusion Service and medical practitioners in the areas serviced by 
Groote Schuur Hospital. However this study is not designed to assess how this has 
affected the management of chronic viral hepatitis because the period of study does 
not adequately cover the period over which interferon has been available at Groote 
Schuur Hospital. A study that should be inclusive of every patient who received 
interferon would need to be undertaken. 
The success rate in the patients who received IFN in this cohort was very low. In the 
HBV cases, only 6 of the 75 patients (8%) in the study group received IFN. Of these 
only 2 responded with clearance of their HBeAg. In 1 patient the follow-up is not 
available as the patient was discharged back to the referring hospital (see pages 72 
and 95). In the 5 patients in whom follow-up is available, 4 were alive at the end of 
1996 and 1 patient had died from liver failure 60 months after IFN therapy to which 
there had been no response. Of the 4 patients alive, 2 of them were the patients who 
had responded to IFN with the loss of HBeAg. They were both lost to follow-up at 36 
and 12 months respectively after the completion of their IFN treatment courses. 
The remaining 2 patients were non-responders to IFN therapy. The one patient has 
complications of established liver cirrhosis with intra-hepatic stones, portal 
hypertension and intractable ascites. This patient has recurrent ward admissions for 
spontaneous bacterial peritonitis, cholangitis and tense ascites that requires regular 
drainage. The last patient initially responded to IFN therapy with the loss of HBeAg 
but relapsed at one year of follow-up. During this period she also developed 
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hypothyroidism as a complication of IFN treatment. Presently she has established 
cirrhosis with a low normal albumin of 35g/l and a mildly deranged clotting profile. 
In the HCV patient group, 5 of 25 patients (20%) received IFN treatment and none of 
them responded (see pages 75 and 98). One patient received the IFN as part of a drug 
trial and the follow-up details are not available. In the remaining four patients, one 
patient had a liver transplant but died 24 months post liver transplantation from 
septicaemia following colon resection surgery for perforated colon diverticuli. One 
patient was lost to follow-up and the other 2 patients are alive with established liver 
cirrhosis. 
Lamivudine use in non-drug trial patients was done in 2 patients of this study cohort. 
In one patient lamivudine was used due the presence of cirrhosis with low platelet and 
leukocyte counts. This patient was alive at the end of the study and this was 2 years 
after starting the lamivudine treatment. The second patient was treated with 
lamivudine after acquiring acute HBV infection 10 months post liver transplantation 
from a household contact. The other patients, who are in the majority, received 
symptomatic therapy for the associated complications of chronic liver disease. The 
emphasis in these patients was on the management of ascites, infections and the 
eradication of oesophageal varices. 
Autoimmune liver disease therapy 
The only therapy that made an impact on the progression of disease was 
immunosuppression in the treatment of AIH or steroid sensitive chronic hepatitis. As 
a result it is not surprising that the follow-up rate of the other chronic hepatitis cases 
was poor. As discussed in Chapter 1, the availability of reasonably effective therapy 
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meant that the AIH and steroid responsive patients required more regular follow-up to 
monitor dosages and the response to treatment. 
All the autoimmune marker positive patients received prednisone. Azathioprine was 
added if there was no biochemical response or if the steroid doses could not be 
tapered down without deterioration in the liver tests. The autoimmune markers that 
are done at Groote Schuur Hospital in the investigation of possible autoimmune liver 
disease are ANF, SMA, AMA and anti-LKMl and 2 antibodies. The patients, who 
had inactive "burnt-out disease" i.e. established cirrhosis with normal liver tests, were 
not treated with immunosuppressive therapy. Only 11.8% (6 out of 51 patients) of the 
cases with AIH who fell into this category and these patients were treated for any 
complications of chronic liver disease that they had at presentation. 
3:2 LIVER TRANSPLANTATION 
There were 13 patients in this study cohort who underwent liver transplantation. Eight 
were male and 5 female. Although the numbers are small, there were no Indian 
patients in this group, Blacks comprised 23.1 % (3 of 13 patients), Coloureds 
comprised 30.8 % ( 4 of 13 patients) and Whites were 46.1 % ( 6 of 13 patients) of the 
whole group. Most of the patients were young or in the 3rd to 5th decade (Figure 36). 
The youngest was 13 years and the oldest was 56 years old. The aetiology of the end-
stage liver disease leading to liver transplantation is summarised in Figure 37. 
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In terms of numbers, the aetiological groups of the transplant patients were: HBV - 2 
patients, HCV - 3 patients, AIH - 3 patients, Cryptogenic chronic hepatitis - 4 patients 
and Cryptogenic steroid sensitive chronic hepatitis - 1 patient. There were no cases 
with drug-induced hepatitis in the transplant group. One of the cryptogenic chronic 
hepatitis patients developed acute HBV infection 1 year after transplantation but has 
done well on lamivudine treatment. 
Table 30 summarises the total adult liver transplants done during the study period. In 
the study patients, there were 5 deaths, one was in the immediate post-surgical period 
and the other deaths were 7 to 36 months post liver transplantation (Table 31). 
TABLE: 30 
Adult liver transplants done 1988-1996 
YEAR TRANSPLANTS DONE STUDY GROUP 
( Chronic hepatitis) 
1988 1 1 
1989 2 
1990 5 3 
1991 4 
1992 6 
1993 6 4 
1994 7 1 
1995 7 4 
1996 6 
TOTAL 44 13 
TABLE: 31 
Causes of death in the liver transplant cases 
DIAGNOSIS CAUSE OF DEATH FOLLOW-UP 
1 HCV Intra-abdominal bleed, adult 1 Week 
respiratory distress syndrome 
2 Cryptogenic chronic Disseminated CMV infection, chronic 7 months 
hepatitis rejection 
3 HCV Perforated colon, septicaemia 24 months 
4 AIH Acute HBV infection 36 months 
5 AIH Chronic rejection, disseminated CMV 36 months 
and aspergillosis infections 
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3:3 DISCUSSION 
3:3.1 Transplantation in chronic viral liver disease 
Liver transplantation for chronic liver disease became available at Groote Schuur 
Hospital in October 1988. The first 10 patients were reported in 1992 and among 
them were 2 cases of HBV chronic hepatitis who are included in this study cohort 
(Robson et al. 1992). Since then 47 liver transplants have been done in adults 
inclusive of the 44 during the study period. The outcome following liver 
transplantation for chronic liver disease has improved in the last decade and the 
management of these patients is still evolving. 
Transplantation in HBV chronic hepatitis results in a high incidence of re-infection 
and progression to chronic hepatitis with cirrhosis often occurring within 2 years 
(Lake et al. 1991 ). This may be associated with a rare histological variant called 
fibrosing cholestatic hepatitis that is rapidly progressive and has a fatal outcome. This 
is typified by the presence of periportal and perisinusoidal fibrosis, ballooned 
hepatocytes with cell loss, pronounced cholestasis and mild inflammatory activity 
(Davies et al. 1991 ). The European Hepatitis Project (EURO HEP) evaluated the 
results of liver transplantation in hepatitis B surface antigen positive patients in 
European centres between 1977 and 1990 (Samuel et al. 1993). This review showed 
that a lower recurrence risk was independently predicted by: 
1. The long-term administration of anti-HBs immunoglobulin for at least six months 
or more. Prophylaxis for 2 months or less had the same outcome as not giving any 
immunoglobulin. 
2. The absence of HBV DNA in serum before transplantation. 
3. The absence of HBeAg in serum before transplantation. 
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A lower risk of recurrence was also associated with HDV superinfection and acute 
fulminant liver disease. The association with HDV superinfection may be due to the 
ability of HDV to switch-off HBV replication (Sureau et al. 1992). 
The treatment strategies for patients with hepatitis B infection undergoing liver 
transplantation should include: 
(a) Patient selection to exclude those with a high level of viral replication before 
transplantation. The patients to be considered are those with acute fulminant 
hepatitis B or D, chronic HDV infection, or chronic HBV infection without 
detectable HBeAg or HBV DNA. 
(b) Modification of immunosuppression to reduce the risk of re-activation. Steroids 
have a deleterious effect and this is likely to be due to the presence of a steroid 
responsive promoter region in the HBV genome. The activation of the promoter 
region results in increased viral replication (Lam et al. 1980, Tur-Kaspa et al. 
1986). For these reasons, the clinical practice is for a rapid reduction in the dose 
of steroids in these patients post liver transplantation. 
(c) Passive immunoprophylaxis with hepatitis B immunoglobulin has now been 
shown to reduce the rate of recurrent hepatitis B infection significantly. In the 
EUROHEP study, the rate of recurrent HBV infection after 3 years was only 30% 
in patients on long-term prophylactic HBsig treatment (for at least six months) 
compared with 67% in those given no prophylaxis (Samuel et al. 1993). However 
the cost is prohibitive and the availability is limited. In 1997 figures, HBsig 
therapy in the United States adds $10 000 - $50 000 to the first year's charges for a 
liver transplant and $5000 - $20 000 to each subsequent year (Terrault and Wright 
1997). Such costs are clearly not affordable in South Africa, which makes the 
transplantation of these patients economically unaffordable. 
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(d) Antiviral treatments pre-transplantation and post-transplantation to prevent graft 
re-infection and avert the recurrence of HBV infection. Interferon-a has the 
theoretical risk of enhancing HLA expression on epithelial cells of the bile ducts 
and lead to allograft rejection. The magnitude of this problem is controversial and 
the risk of acute rejection cannot be quantified (Wright T 1994,Terrualt 1996, 
Terrualt 1997). 
The use of nucleoside analogues has had good results in both transplant and non-
transplant cases. In liver transplant patients, lamivudine given as 100mg daily for 4 
weeks before the transplant showed undetectable HBV DNA concentrations or 
borderline positive results by bDNA assay (Perrillo et al. 1996). 
The HBV cases transplanted at Groote Schuur hospital have done well. Two cases 
were transplanted and another patient acquired acute HBV infection post-
transplantation. One case was known to be HBV infected pre-transplantation. This 
patient was done in April 1990 and had a negative HBeAg, positive HBsAg and 
HBeAb pre-transplantation. HBV DNA levels were not done because the assay was 
not available at Groote Schuur Hospital at the time. Graft re-infection occurred in 
September 1990 and the patient became HBeAg positive. IFN therapy was started but 
this was stopped after the patient developed severe depression and became suicidal. 
The patient is alive and has good graft function. The other patient had negative 
serological markers for HBV infection pre-transplant. However on 
immunohistochemistry staining of the explanted liver, the HBsAg was positive. This 
patient is alive and also has good graft function. The patient who had post-transplant 
acute HBV was transplanted for cryptogenic chronic hepatitis in November 1995 and 
acquired HBV infection from a household contact in September 1990. Lamivudine 
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was given and over the years she has done very well. The current results show that 
she is now negative on testing for HBV DNA, HBsAg, and HBeAg. 
In the three patients who were transplanted for HCV infection, 2 have since died and 
1 is still alive. Patient number 1 in Table 31 died a week post transplantation after 
developing an adult respiratory distress syndrome 2 days post-surgery and intra-
abdominal bleeding 6 days later. Patient number 3 in Table 31 died 2 years following 
liver transplantation due to complications of colon resection surgery after diverticuli 
perforation. The patient who is alive was transplanted in 1993. He did not receive IFN 
at any stage and is still HCV PCR positive but with good synthetic liver function. 
One of the transplant patients had an incidental hepatocellular carcinoma (HCC) 
found on the histology of the ex planted liver. This patient is still alive and there has 
been no evidence of tumour recurrence. The management of HCC in this series of 
patients has been discussed earlier (see section 2:3.8 page 84). 
3:3.2 Prevention of chronic hepatitis 
The management of chronic hepatitis today should involve preventative measures, the 
treatment of complications of chronic liver disease and the use of "disease modifying 
therapies" where appropriate. The prevention of chronic hepatitis is possible in drug-
induced liver disease and chronic viral hepatitis, as these causes are amenable to 
interventions that can prevent disease. 
In chronic viral hepatitis, education, improvement of public health, follow-up of cases 
and their close contacts, screening of appropriate target groups and vaccination are 
necessary to impact on the incidence of disease in the population. Education can be 
effected through the print and electronic media, school education programmes and via 
institutions such as the Blood Transfusion Services which have frequent and regular 
contact with communities. The Western Province Blood Transfusion Service 
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(WPBTS) provides such a service. The WPBTS also initiates the follow-up and 
assessment of clients who test positive for hepatitis B or C serological markers. Such 
patients are referred to the liver clinic at Groote Schuur hospital for assessment and 
initiation of contact follow-up and education. These clinic visits are important because 
they provide an opportunity to assess the individual patient for interferon therapy and 
also to effect the follow up of close contacts of the patient, who may benefit from 
vaccination. If already infected with HBV, the contacts would also require a clinical 
assessment for possible interferon use. 
The provision of appropriate sanitation, clean drinking water and uncontaminated 
food are important to modify risk factors for acquiring viral hepatitis. The gross 
under-notification of cases of hepatitis impacts negatively on the ability of the health 
system to follow-up contacts of cases and keep reliable data on viral hepatitis. 
Accurate data is important for identifying trends and for planning health interventions 
by Government. In South Africa, it is estimated that due to under-reporting, the 
national incidence of hepatitis B is at least 7 times higher than that calculated from 
notification data (Abdool Karim 1991 ). 
Screening is the routine investigation of an apparently healthy population to detect an 
unsuspected condition for which treatment would be beneficial. Therefore to justify 
the exercise, the detection test should be specific and sensitive enough to pick up 
disease and the treatment good enough to justify the screening procedure. If used 
successfully, screening will prevent infection or transmission and identify those cases 
that require vaccination for hepatitis B. Screening has already been used for blood 
donations to prevent the transmission of HBV, HCV and other transmittable diseases 
with remarkable success. The screening of pregnant women is important in the 
strategy to control hepatitis B virus infection because the use of hepatitis B 
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immunoglobulin and immunisation of infants is highly effective in preventing vertical 
transmission of hepatitis B virus. Universal vaccination against hepatitis B virus 
infection of newborn babies and infants under the age of 1 year was started in South 
Africa in April 1995. The vaccine in use is a plasma derived flash heated vaccine 
(Hepaccine-B). This is given at birth, 1 and 6 months of age to coincide with the other 
clinic visits for immunisations. The vaccine is given intramuscularly in the deltoid 
muscle at a dose of 1 Og per dose in children and 20g per dose in adults. 
Administration in the buttock has been shown to be less effective and should not be 
used (Buchel et al. 1994). A booster injection is recommended for every 5 years to 
maintain protective levels of anti-HBV immunoglobulin. A recent study has shown 
the benefit of universal vaccination in Taiwan where the average annual incidence of 
hepatocellular carcinoma is showing dramatic reductions in children following the 
introduction of a vaccination programme for HBV infection (Chang et al. 1997). The 
other population groups who should be targeted for vaccination include: 
I. Recipients of blood products on a regular basis. Those with clotting disorders who 
receive factor concentrates and those with hypo-immune disorders that require 
regular immunoglobulin infusions. 
2. People at occupational risk of acquiring HBV infection. This includes health care 
workers and students, staff at mental institutions who are at risk to assaults, bites 
and needle stick injuries. 
3. Patients on haemodialysis and those in mental institutions and special schools. 
4. Sexual and household contacts of HBV carriers. Vaccination should be combined 
with education about the spread of HBV and how to minimise the risk of 
transmission. 
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5. Those at risk of sexual transmission i.e. commercial sex workers and homosexual 
and bisexual men (Practices advisory committee 1991 ). 
6. Non-immune travellers who are going to stay in an endemic area for more than six 
months. Vaccination should ideally begin 6 months before travel to allow for the 
completion of the vaccination series. 
In drug-induced hepatitis, the only effective preventive measure available is the 
education of the health workers and their patients. The severity and incidence of this 
problem can only be reduced through safe prescription practises and the immediate 
cessation of any drug that a patient who presents with jaundice and raised liver 
enzymes may be using. Clearly a causality assessment has to be done by the attending 
doctor but any potential hepatotoxin is best stopped until a cause for the liver 
dysfunction can be established (see section 1:3.4(d) pages 30 - 32). 
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CHAPTER 4: 
REVIEW AND CONCLUSIONS 
This study has raised a number of interesting questions that need further investigation 
and has also exposed the limitations of analysing data that has not been uniformly 
collected and recorded. These points can be discussed under the following 
subheadings: 
I. The quality of the available data. 
2. Treatments used and the use of liver biopsy in managing chronic hepatitis. 
3. The subtypes of AIH and the need to further evaluate the nature of the diagnostic 
categories of chronic hepatitis and cryptogenic steroid sensitive chronic hepatitis 
4:1 QUALITY OF DATA AVAILABLE 
The data available was not consistent in its detail and accuracy. The best detail was 
available from the liver clinic records where the emphasis was more on the 
management of the chronic liver disease. Even so, details of factors like alcohol 
consumption were universally poorly recorded and a comment on the impact of 
alcohol in chronic hepatitis or the development of HCC can not be made from this 
study. It was clear that the liver clinic itself needs an easily accessible computerised 
database and that for uniformity and accuracy, a standard clinic form for recording 
essential details would be ideal. A good database would allow for: 
1. Retrospective studies to monitor disease prevalence and admission trends. 
2 Easier auditing of patient management at the clinic to see where changes may be 
necessary to improve patient care. 
CHAPTER: 4 REVIEW AND CONCLUSIONS - 119 -
3 The tracing of patients in the event of new therapies or new diagnostic procedures 
becoming available. 
4. Linking of patient details to pathology records and possibly the storage of blood 
and tissue samples for future study and reference. 
This is important when considering the need currently to further evaluate the patients 
who fall into the diagnostic categories of cryptogenic chronic hepatitis. 
4:2 TREATMENTS AVAILABLE AND THE USE OF LIVER BIOPSY 
The limited therapies available in the past impacted negatively on the ability to 
sustain long follow-up periods in most patients other than the AIH cases. The 
availability of liver transplantation in 1988 and interferon in the 1990s improved the 
treatment modalities available to patients at Groote Schuur Hospital and this has 
improved the outcome in patients with chronic liver failure. Transplantation in 
patients with HBV related liver failure is unfortunately not economically viable in the 
South African setting despite this being the biggest cause of chronic liver disease in 
sub-Saharan Africa. The major reason is the cost of HBs-immunoglobulin, which is 
necessary for the survival of the graft (see section 3:3.1). 
The use of liver biopsy is increasing and from the analysis of the biopsies done in this 
patient cohort, all modes of liver biopsy are in increasing use. This suggests that every 
attempt is being made to obtain liver tissue in the assessment of these patients at the 
liver clinic. Of interest to the author was the fact that the use of trans jugular liver 
biopsies has continued to increase (Table 17, Figure 17 on pages 69, 70). This is so 
because the early use of this procedure was by the surgical hepato-biliary team at 
Groote Schuur Hospital in their studies of bleeding oesophageal varices in portal 
hypertension. The continued use of the transjugular liver biopsy method presently is a 
reflection of other transjugular liver biopsy procedures being done which are not 
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related to any study protocol. This is most likely due to the continued late presentation 
of patients at Groote Schuur Hospital with established cirrhosis and therefore difficult 
to biopsy livers. 
4:3 PATIENT GROUPS AND AIH SUBTYPES 
The patients sub-groups documented in this study have shown the presence of a group 
of patients who therapeutically behave like AIH but do not have the markers of 
autoimmunity on testing i.e. the cryptogenic steroid sensitive chronic hepatitis group. 
This group warrants further study to characterise their immunological status and 
clinical response to immunosuppression treatment long term as compared to classical 
AIH. While the liver clinic at Groote Schuur Hospital has been good in separating the 
steroid sensitive patients and treating them in the same way as the AIH patients, these 
patients require further characterisation in every respect. It is possible that the 
Coloured population of the Western Cape in particular has an immune phenotype that 
makes them susceptible to autoimmune hepatitis. From Table I 2, page 55, the female 
Coloured population comprises 47.6% of the study population women (59 of 124 
women) and 26% of the whole group (59 of 226 patients). While the rest of the racial 
groups had equal numbers of both sexes affected in the Coloured population the male: 
female ratio was 1: 1.7. All these clues tend to suggest that this population may have a 
unique genetic pool resulting in the high incidence of a group of patients who have 
chronic liver disease indistinguishable from AIH but have negative autoimmune 
markers on standard testing. This will be the subject of a study arising from this work. 
The accompanying group of cryptogenic chronic hepatitis also needs to have their 
virological and immune status further looked at to rule out the possibility of missed 
chronic hepatitis C infection or drug aetiologies. 
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APPENDIX A DATA CAPTURE FORMS 
Histology: 
Liver biopsies done: 1. ________________ _ 
2. -----------------
3. -----------------
Histological diagnosis: _________________ _ 
Scoring of Histological Inflammatory Activity and Staging/Degree of fibrosis: 
* 
* 
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APPENDIX Bl HISTOPATHOLOGY ASSESSMENT FORMS - 143 -
Grading of inflammation (Ishak et al 1995) 
Grading Component SCORE 
Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent 0 
Mild (focal, few portal areas) 1 
Miki/moderate (focal, most portal areas) 2 
Moderate ( continuous around<50% of portal tracts or septa) 3 




Focal confluent necrosis 1 
Zone 3 necrosis in some areas 2 
Zone 3 necrosis in most areas 3 
Zone 3 necrosis+ occasional portal-central (P-C) bridging 4 
Zone 3 necrosis+ multiple P-C bridging 5 
Panacinar or multiacinar necrosis 6 
Sub-total 
Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
Absent 0 
One focus or less per lOx objective 1 
Two to four foci per 1 Ox objective 2 
Five to ten foci per 1 Ox objective 3 




Mild, some or all portal areas 1 
Moderate, some or all portal areas 2 
Moderate/marked, all portal areas 3 
Marked, all portal areas 4 
Sub-total 
TOTAL SCORE 
Staging of fibrosis 
Change Score 
No fibrosis 0 
Fibrous expansion of some portal tracts +/- short fibrous septa 1 
Fibrous expansion of most portal tracts, +/- short fibrous septa 2 
Fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging 3 
Fibrous expansion of portal areas with marked bridging P-P and portal to central (P-C) 4 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 5 
Cirrhosis, probable or definite 6 
TOTAL SCORE 
APPENDIX B2 HISTOPATHOLOGY ASSESSMENT FORMS - 144-
BEDOSSA ALGORITHM FOR THE EVALUATION 
OF HISTOLOGICAL ACTIVITY (Bedossa et al. 1996) 
N=O ----- A=O 
____ A=1 
A=2 
PMN=1 LN=O, 1 ----A=1 
~N=2 




PMN=3 ____ __:LN=O, 1,2--~ A=3 
PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate; 3, severe; LN, lobular 
necrosis; 0, no or mild; 1, moderate; 2, severe; A, histological activity; 0, none; 1, 
mild; 2, moderate; 3, severe. 
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Figure 1 Figure 2 
Figure 3 Figure 4 
Figure 5 Figure 6 
